0001493152-26-023197 | 10-Q | XBRL Viewer

Print Document

SCHEDULE OF NON VESTED RESTRICTED ACTIVITY (Details)	3 Months Ended
SCHEDULE OF NON VESTED RESTRICTED ACTIVITY (Details)	Mar. 31, 2026 shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Nonvested as of December 31, 2025
Granted	1,500,000,000
Vested and issued
Forfeited
Nonvested as of March 31, 2026	1,500,000,000
Restricted shares outstanding beginning balance	678,679
Forfeited
Restricted shares outstanding ending balance	678,679
Vested restricted shares	678,679
Unvested restricted shares
Vested and unvested restricted shares total	678,679
Performance Shares [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Nonvested as of December 31, 2025
Granted	500,000,000
Vested and issued
Forfeited
Nonvested as of March 31, 2026	500,000,000
Performance shares And AUM [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Nonvested as of December 31, 2025
Granted	1,000,000,000
Vested and issued
Forfeited
Nonvested as of March 31, 2026	1,000,000,000

GOODWILL AND INTANGIBLE ASSETS (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Intangible Asset, Indefinite-Lived [Line Items]
Amortization expenses	$ 1,479	$ 3
Trade Names [Member]
Intangible Asset, Indefinite-Lived [Line Items]
Amortization expenses	$ 128	0
Finite lived intangible asset, useful life	7 years 4 months 24 days
Developed Technology Rights [Member]
Intangible Asset, Indefinite-Lived [Line Items]
Amortization expenses	$ 1,260	0
Finite lived intangible asset, useful life	9 years 2 months 12 days
Legal Contact [Member]
Intangible Asset, Indefinite-Lived [Line Items]
Amortization expenses	$ 86	0
Finite lived intangible asset, useful life	7 years 2 months 12 days
Patents [Member]
Intangible Asset, Indefinite-Lived [Line Items]
Amortization expenses	$ 5	$ 3
Finite lived intangible asset, useful life	13 years 6 months
Compliance Framework [Member]
Intangible Asset, Indefinite-Lived [Line Items]
Finite lived intangible asset, useful life	6 years 2 months 12 days

- Definition

Amount of amortization expense for finite-lived intangible asset. Excludes goodwill and capitalized cost for software to be sold, leased, or marketed.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 28
-Subparagraph (b)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-28

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482558/350-40-50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-11

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 18
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-18

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476153/220-40-55-24

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-12

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147476148/220-40-50-6

+ Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-3

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-38

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-31

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479876/805-20-55-14

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Name Accounting Standards Codification
-Section 55
-Paragraph 40
-SubTopic 30
-Topic 350
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482640/350-30-55-40

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482686/350-30-45-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482665/350-30-50-2

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

3 Months Ended

Mar. 31, 2026

Accounting Policies [Abstract]

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

NOTE 3 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

Basis of Presentation

The unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and applicable rules and regulations of the SEC regarding interim financial reporting. Certain information and note disclosures normally included in the financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to such rules and regulations. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the consolidated financial statements and accompanying notes included in our Annual Report on Form 10-K for the year ended December 31, 2025.

Basis of Consolidation

The accompanying unaudited condensed consolidated financial statements include the accounts of Streamex Corp. and its consolidated subsidiaries, including variable interest entities (“VIEs”) for which the Company is determined to be the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation. Noncontrolling interests represent the portion of equity interests in consolidated subsidiaries not attributable to the Company and are reported as a separate component of stockholders’ equity.

During the three months ended March 31, 2026, the Company determined that it became the primary beneficiary of Streamex Ltd., a Cayman Islands exempted company, under the VIE model in ASC 810, Consolidation. The Company became the primary beneficiary upon the formation and initial capitalization of Streamex Ltd. in February 2026, at which time the Company obtained the power to direct the activities of Streamex Ltd. that most significantly impact its economic performance and the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, Streamex Ltd. has been consolidated from the date the Company became the primary beneficiary. See Note 9, Streamex Ltd. (VIE), for additional information.

Use of estimates

The preparation of unaudited condensed consolidated financial statements in conformity with GAAP requires us to make estimates and assumptions that affect the amounts reported and disclosed in the financial statements and the accompanying notes. Changes in circumstances could cause actual results to differ materially from these estimates.

Foreign Currency Translation

The functional currency of the Company’s Canadian subsidiary, ExchangeCo, is the Canadian dollar. Assets and liabilities denominated in Canadian dollars are translated into U.S. dollars at the exchange rate in effect at the balance sheet date, while revenues and expenses are translated at the average exchange rate for the period. Resulting translation adjustments are recorded in accumulated other comprehensive income (loss) as a separate component of stockholders’ equity.

Marketable Securities

The Company’s marketable securities consist of equity securities measured at fair value with changes in fair value recognized in earnings, in accordance with ASC 321, Investments — Equity Securities. Fair value is determined using quoted market prices in active markets (Level 1).

Gold Assets

The Company, through its consolidated variable interest entity Streamex Ltd., holds physical gold bullion. Gold purchased for the purpose of backing GLDY Token obligations is recorded at cost, which includes the purchase price and directly attributable transaction costs, and is classified as “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet. The Company classifies the gold as a non-current asset because the gold is acquired and held to support the long-term GLDY Token program and related leasing activities, and management does not expect to liquidate the gold within the next twelve months. The gold is accounted for as a long-lived tangible asset within the scope of ASC 360. Cost is determined on a specific identification basis. Ongoing storage, insurance, and administrative custody costs are expensed as incurred.

Management evaluates the gold for impairment under ASC 360-10-35 when events or changes in circumstances indicate that the carrying amount may not be recoverable. Such events may include, among other factors, a significant decline in market prices, adverse changes in legal, regulatory, or custodial conditions, or other factors affecting the Company’s ability to access or realize economic benefits from the asset. The Company considers both market-based and asset-specific factors in assessing whether an impairment indicator exists. Once classified as held for sale, the gold is carried at the lower of carrying amount or fair value less cost to sell, with any write-downs recognized in earnings and subsequent increases recognized only to the extent of previously recognized losses. No impairment charges were recorded during the three months ended March 31, 2026.

Gold that has been committed for sale or that management has committed to a plan of sale is reclassified to “Other assets held for sale” and measured at the lower of carrying amount or fair value less costs to sell in accordance with ASC 360.

Concentration of Assets

As of March 31, 2026, the Company’s consolidated assets totaled $173,317, of which approximately 33% ($56,387) were located in the United States and 67% ($116,930) were located in Canada. The Canadian assets are held through ExchangeCo, a wholly owned subsidiary of the Company, and relate to the Company’s Streamex Exchange business. These assets consist primarily of goodwill and intangible assets ($111,931), cash ($4,907), sales tax receivable ($59), and prepaid expenses and other assets ($33).

As of March 31, 2026, the Company’s cash of $6,859 was held across the following jurisdictions: approximately $1,952 in the United States (including $60 held by Streamex Ltd., the Company’s consolidated VIE, in accounts in the United States and the Cayman Islands), and approximately $4,907 in Canada through ExchangeCo. Cash held in Canada is denominated primarily in U.S. dollars and is not subject to material repatriation restrictions.

The Company evaluates geographic concentrations in accordance with ASC 275, Risks and Uncertainties, and considers potential exposure to economic, regulatory, and currency-related risks. While the Canadian-based assets represent a significant portion of consolidated assets, they are not currently subject to material operational, legal, or foreign exchange restrictions. Management believes that the Company is not exposed to heightened risk from geographic concentration, given the nature of the assets, the stability of the Canadian jurisdiction, and the strategic alignment of the Streamex Exchange business with the Company’s broader operations.

Net Income (loss) Per Common Share

The Company computes earnings (loss) per share in accordance with Accounting Standards Codification subtopic 260, Earnings Per Share (“ASC 260”). Basic earnings (loss) per common share is computed by dividing net income (loss) attributable to the Company’s common stockholders by the weighted-average number of shares of common stock outstanding during the period, including exchangeable shares that are economically equivalent to the Company’s common stock.

The Company has outstanding exchangeable shares issued by a consolidated subsidiary that are economically equivalent to the Company’s common stock in all material respects, including rights to dividends and participation in earnings, and are exchangeable on a one-for-one basis into shares of the Company’s common stock at the option of the holders. The exchangeable shares are classified within stockholders’ equity and are included in the weighted-average shares outstanding used in the calculation of basic earnings (loss) per common share because these shares participate equally with the Company’s common stock in undistributed net income (loss).

Diluted earnings per common share is computed by giving effect to all potentially dilutive securities and other contracts to issue common stock using the treasury stock method and the if-converted method, as applicable, in accordance with ASC 260. Potentially dilutive securities may include stock options, warrants, restricted stock units, and other equity awards (treasury stock method), as well as the Company’s convertible preferred stock and convertible debt, including the secured convertible debentures (if-converted method). Under the if-converted method, convertible instruments are assumed to have been converted at the beginning of the period (or at issuance, if later), and related preferred dividends and/or interest expense (net of tax), as applicable, are adjusted in the determination of net income available to common stockholders.

In periods in which the Company reports a net loss, basic and diluted loss per share are the same, as the inclusion of stock options, warrants, restricted stock units, convertible preferred stock, convertible debt and other potentially dilutive securities would be antidilutive. Accordingly, such securities are excluded from the computation of diluted loss per share.

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

	March 31,		March 31,
	2026		2025
Series C convertible preferred stock		434,845		564,234
Options to purchase common stock		2,921,000		2,486,000
Performance-based restricted stock units		1,500,000		-
Warrants to purchase common stock		1,647,885		5,577,260
Restricted stock units to acquire common stock		4,583,375		1,160,830
Totals		11,087,105		9,788,324

Recently adopted accounting pronouncements

In July 2025, the FASB issued ASU 2025-05, Financial Instruments-Credit Losses (Topic 326): Measurement of Credit Losses for Accounts Receivable and Contract Assets. This standard provides all entities with a practical expedient to assume that current conditions as of the balance sheet date do not change for the remaining life of the current accounts receivable and current contract assets. ASU 2025-05 is effective for fiscal years beginning after December 15, 2025 and interim periods within those fiscal years, with early adoption permitted. The Company adopted ASU 2025-05 in 2026 and the adoption had no material impact on our unaudited condensed consolidated financial statements.

Recently issued accounting pronouncements not yet adopted

In November 2024, the FASB issued ASU 2024-03, “Disaggregation of Income Statement Expenses” (“ASU 2024-03”). ASU 2024-03 requires disclosure of the nature of expenses included in the income statement in response to longstanding requests from investors for more information about an entity’s expenses. The new standard requires disclosures about specific types of expenses included in the expense captions presented on the face of the income statement and disclosures about selling expenses. As amended by ASU 2025-01, ASU 2024-03 is effective for annual reporting periods beginning after December 15, 2026, and interim reporting periods within annual reporting periods beginning after December 15, 2027. The Company is currently evaluating ASU 2024-03 and does not expect it to have a material effect on the Company’s unaudited condensed consolidated financial statements.

In May 2025, the FASB issued ASU No. 2025-03, Business Combinations (Topic 805) and Consolidation (Topic 810): Determining the Accounting Acquirer in the Acquisition of a Variable Interest Entity (“VIE”), which provides clarifying guidance on determining the accounting acquirer in certain transactions involving VIEs. The update aims to improve consistency and comparability in financial reporting. The guidance will be effective for annual periods beginning after December 15, 2026, including interim periods within those annual periods. Early adoption is permitted. Upon adoption, the guidance will be applied prospectively. The Company is currently evaluating the provisions of the amendments and the impact on its future financial statements.

In September 2025, the FASB issued ASU 2025-06, Intangibles-Goodwill and Other-Internal-Use Software (Subtopic 350-40): Targeted Improvements to the Accounting for Internal-Use Software, to modernize the accounting guidance for internal-use software costs. The standard removes all references to software development project stages and instead requires capitalization when (i) management has authorized and committed to funding the software project and (ii) it is probable that the project will be completed and the software will be used to perform the function intended. ASU 2025-06 is effective for fiscal years beginning after December 15, 2027 and interim periods within those fiscal years, with early adoption permitted. The Company is currently evaluating the impact of adopting ASU 2025-06.

LIQUIDITY	3 Months Ended
Mar. 31, 2026
Organization, Consolidation and Presentation of Financial Statements [Abstract]
LIQUIDITY	NOTE 2 – LIQUIDITY As of March 31, 2026, we had working capital of approximately $42,602 and cash of $6,859. For the three months ended March 31, 2026, we used $10,179 in operating activities, used $1,500 in investing activities, and used $1,637 in financing activities, primarily reflecting the repayment of the remaining outstanding balance on the secured convertible debentures of approximately $38.5 million, substantially offset by net proceeds of approximately $37.2 million from an underwritten public offering completed in January 2026. During the three months ended March 31, 2026, the Company strengthened its liquidity position through financing transactions and asset monetization activities and eliminated its outstanding convertible debt. In January 2026, the Company completed an underwritten public offering generating net proceeds of approximately $37.2 million. The Company also received approximately $10.1 million from the sale of marketable securities and approximately $26.4 million from the sale of gold bullion that had been classified as held for sale as of December 31, 2025. In February 2026, following a partial conversion of the secured convertible debentures into common stock, the Company repaid the remaining outstanding balance for an aggregate cash payment of approximately $38.5 million, and all related security interests were released. We expect to continue incurring operating losses and negative cash flows until our products, including the Streamex Exchange’s digital asset infrastructure and PURE EP™ Platform initiatives, achieve sustained commercial success. Although the PURE EP™ Platform is commercially available, revenues to date have not been material, and the timing and extent of future revenues remain uncertain. The Company launched GLDY and began accepting subscriptions; however, revenues to date have not been material. We expect to incur additional costs related to software development, regulatory compliance, and strategic partnerships prior to the commencement of any material revenue-generating activities. The timing and extent of any future revenues will depend on, among other things, continued investor adoption of GLDY, completion of development milestones, regulatory considerations, market conditions, and the successful commercialization of the Streamex Exchange platform and related offerings. Based on our existing cash and working capital position, management believes that the Company has the ability to continue as a going concern for at least one year from the issuance date of the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. The Company believes it will have sufficient liquidity to meet its anticipated working capital requirements, capital expenditures, and other liquidity needs during that period.

LIQUIDITY

3 Months Ended

Mar. 31, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

LIQUIDITY

NOTE 2 – LIQUIDITY

As of March 31, 2026, we had working capital of approximately $42,602 and cash of $6,859. For the three months ended March 31, 2026, we used $10,179 in operating activities, used $1,500 in investing activities, and used $1,637 in financing activities, primarily reflecting the repayment of the remaining outstanding balance on the secured convertible debentures of approximately $38.5 million, substantially offset by net proceeds of approximately $37.2 million from an underwritten public offering completed in January 2026.

During the three months ended March 31, 2026, the Company strengthened its liquidity position through financing transactions and asset monetization activities and eliminated its outstanding convertible debt. In January 2026, the Company completed an underwritten public offering generating net proceeds of approximately $37.2 million. The Company also received approximately $10.1 million from the sale of marketable securities and approximately $26.4 million from the sale of gold bullion that had been classified as held for sale as of December 31, 2025. In February 2026, following a partial conversion of the secured convertible debentures into common stock, the Company repaid the remaining outstanding balance for an aggregate cash payment of approximately $38.5 million, and all related security interests were released.

We expect to continue incurring operating losses and negative cash flows until our products, including the Streamex Exchange’s digital asset infrastructure and PURE EP™ Platform initiatives, achieve sustained commercial success. Although the PURE EP™ Platform is commercially available, revenues to date have not been material, and the timing and extent of future revenues remain uncertain. The Company launched GLDY and began accepting subscriptions; however, revenues to date have not been material. We expect to incur additional costs related to software development, regulatory compliance, and strategic partnerships prior to the commencement of any material revenue-generating activities. The timing and extent of any future revenues will depend on, among other things, continued investor adoption of GLDY, completion of development milestones, regulatory considerations, market conditions, and the successful commercialization of the Streamex Exchange platform and related offerings.

Based on our existing cash and working capital position, management believes that the Company has the ability to continue as a going concern for at least one year from the issuance date of the unaudited condensed consolidated financial statements included in this Quarterly Report on Form 10-Q. The Company believes it will have sufficient liquidity to meet its anticipated working capital requirements, capital expenditures, and other liquidity needs during that period.

- Definition

The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.

+ References + Details

SEGMENT REPORTING (Details Narrative)	3 Months Ended
SEGMENT REPORTING (Details Narrative)	Mar. 31, 2026 Integer
Segment Reporting [Abstract]
Number of reportable segment	1

STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)				1 Months Ended	3 Months Ended		12 Months Ended
STOCKHOLDERS’ EQUITY (Details Narrative) - USD ($)	Jan. 22, 2026	Nov. 04, 2025	Jan. 12, 2024	Jan. 31, 2026	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025	Mar. 16, 2026
Class of Stock [Line Items]
Preferred stock, shares authorized					1,000,000		1,000,000
Preferred stock, par value					$ 0.001		$ 0.001
Issued price					$ 4.00
Conversion of stock, shares converted					24,571,166
Common stock shares, authorized					500,000,000		500,000,000
Common stock share par value					$ 0.001		$ 0.001
Common stock shares, issued					97,721,696		49,805,275
Common stock shares, outstanding					97,721,696		49,805,275
Exchangeable of common shares outstanding					83,420,765		107,991,931
Sold to investors		109,070,079
Share price			$ 3.00					$ 3.00
Gross proceed for stock offering				$ 37,200,000	$ 37,184,000
Other offering expenses	$ 3,066
Proceeds from issuance of common stock	37,184					$ 818,000
Sales Agreement [Member]
Class of Stock [Line Items]
Issuance cost					4,500,000
Over-Allotment Option [Member]
Class of Stock [Line Items]
Adjustments to addtional paid issuance costs	1,750,000
Gross proceed for stock offering	$ 40,250
Investor [Member]
Class of Stock [Line Items]
Sold to investors			11,666,667
Subscription amount					$ 5,000,000
Series A Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					200		200
Series B Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					600		600
Series C Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					4,200		4,200
Preferred stock, shares issued					105		105
Preferred stock, shares outstanding					105		105
Dividends payable					$ 123,000		$ 121,000
Dividends payable					$ 1,175,000		$ 1,153,000
Series D Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					1,400		1,400
Series E Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					1,000		1,000
Series F Preferred Stock [Member]
Class of Stock [Line Items]
Preferred stock, shares authorized					200,000		200,000
Preferred Stock [Member]
Class of Stock [Line Items]
Temporary equity, liquidation preference					$ 1.00
Convertible Preferred Stock [Member]
Class of Stock [Line Items]
Common stock conversion price					0.3197
Issued price					$ 1,000
Conversion of stock, shares converted					434,845
Shares issued for services					106,412
Conversion price					$ 1.1593
Effective price					$ 0.3197

SCHEDULE OF RESTRICTED STOCK UNITS GRANTS (Details) - USD ($)
shares in Thousands, $ in Thousands

3 Months Ended

Mar. 31, 2026

Mar. 31, 2025

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted

2,965,000

Stock issued during the period, value

$ 1,724

$ 3,882

Restricted Stock Units (RSUs) [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock issued during the period, value

^[1]

$ 8,445

One One Two Thousand Twenty Six [Member] | Third Party Consultant [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted

250,000

Share based compensation arrangement by share-based payment award, award vesting rights

25,000 immediately; remainder quarterly

One One Two Thousand Twenty Six [Member] | Third Party Consultant [Member] | Restricted Stock Units (RSUs) [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock issued during the period, value

^[1]

$ 758

One Eight Two Thousand Twenty Six [Member] | Interim Executive Chairman [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted

100,000

Share based compensation arrangement by share-based payment award, award vesting rights

4 equal quarterly installments over 1 year

One Eight Two Thousand Twenty Six [Member] | Interim Executive Chairman [Member] | Restricted Stock Units (RSUs) [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock issued during the period, value

^[1]

$ 321

One Eight Two Thousand Twenty Six [Member] | Chief Executive Officier [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted

1,000,000

Share based compensation arrangement by share-based payment award, award vesting rights

100,000 on May 15, 2026; 900,000 in 16 quarterly installments over 4 years

One Eight Two Thousand Twenty Six [Member] | Chief Executive Officier [Member] | Restricted Stock Units (RSUs) [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock issued during the period, value

^[1]

$ 3,210

One Twenty Seven Two Thousand Twenty Six [Member] | Third Party Consultant [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted

125,000

Share based compensation arrangement by share-based payment award, award vesting rights

16 quarterly installments over 4 years

One Twenty Seven Two Thousand Twenty Six [Member] | Third Party Consultant [Member] | Restricted Stock Units (RSUs) [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock issued during the period, value

^[1]

$ 456

Two One Two Thousand Twenty Six [Member] | Third Party Consultant [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted

500,000

Share based compensation arrangement by share-based payment award, award vesting rights

300,000 immediately; 200,000 in 4 quarterly installments over 12 months

Two One Two Thousand Twenty Six [Member] | Third Party Consultant [Member] | Restricted Stock Units (RSUs) [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock issued during the period, value

^[1]

$ 1,790

Three Three Two Thousand Twenty Six [Member] | Third Party Consultant [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted

425,000

Share based compensation arrangement by share-based payment award, award vesting rights

212,500 immediately; 125,000 on Jun 3; 87,500 on Sep 3, 2026

Three Three Two Thousand Twenty Six [Member] | Third Party Consultant [Member] | Restricted Stock Units (RSUs) [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock issued during the period, value

^[1]

$ 876

Three Sixteen Two Thousand Twenty Six [Member] | Third Party Consultant [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted

65,000

Share based compensation arrangement by share-based payment award, award vesting rights

5,000 immediately; remainder monthly

Three Sixteen Two Thousand Twenty Six [Member] | Third Party Consultant [Member] | Restricted Stock Units (RSUs) [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock issued during the period, value

^[1]

$ 119

Three Sixteen Two Thousand Twenty Six [Member] | Chief Financial Officer [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Share-Based Compensation Arrangement by Share based payment award, non option equity instruments, granted

500,000

Share based compensation arrangement by share-based payment award, award vesting rights

16 quarterly installments over 4 years

Three Sixteen Two Thousand Twenty Six [Member] | Chief Financial Officer [Member] | Restricted Stock Units (RSUs) [Member]

Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]

Stock issued during the period, value

^[1]

$ 915

[1]	Grant-date fair value (“GDFV”)

SCHEDULE OF OUTSTANDING TO WARRANTS (Details)	Mar. 31, 2026 $ / shares shares
Warrants exercise price \| $ / shares	$ 5.00
Warrants rights outstanding \| shares	473,772
Bio Sig AI Sciences Inc [Member]
Warrants exercise price \| $ / shares	$ 1.00
Warrants rights outstanding \| shares	130,500

SCHEDULE OF PROPERTY AND EQUIPMENT (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Property, Plant, and Equipment [Line Items]
Total	$ 1,036	$ 1,036
Less accumulated depreciation	(1,024)	(1,011)
Property and equipment, net	12	25
Computer Equipment [Member]
Property, Plant, and Equipment [Line Items]
Total	531	531
Furniture and Fixtures [Member]
Property, Plant, and Equipment [Line Items]
Total	109	109
Testing and Demo Equipment [Member]
Property, Plant, and Equipment [Line Items]
Total	312	312
Leasehold Improvements [Member]
Property, Plant, and Equipment [Line Items]
Total	$ 84	$ 84

- Definition

Amount of accumulated depreciation, depletion, and amortization of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.

+ References + Details

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 905
-SubTopic 360
-Name Accounting Standards Codification
-Section 25
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478704/905-360-25-4

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482338/360-10-05-3

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 30
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482222/360-10-30-2

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 3
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482338/360-10-05-3

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482338/360-10-05-3

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 05
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482338/360-10-05-3

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482558/350-40-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A

+ Details

- Definition

Amount, after accumulated depreciation, depletion, and amortization, of property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 360
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478443/942-360-45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 360
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478451/942-360-50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 842
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478964/842-20-50-7A

Reference 8: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

+ Details

GOLD ASSETS

3 Months Ended

Mar. 31, 2026

Deferred Costs, Capitalized, Prepaid, and Other Assets Disclosure [Abstract]

GOLD ASSETS

NOTE 8 – GOLD ASSETS

Gold Bullion — Held for Sale (Sold February 2026)

As of December 31, 2025, the Company held LBMA Good Delivery gold bullion (the “Gold”) on an allocated, physically segregated basis in secure vaults operated by Brink’s Global Services USA, Inc. (“Brink’s”) and maintained the Gold in a securities account with Gold Bullion International, LLC (“GBI”). The aggregate carrying value of the Gold as of December 31, 2025 was approximately $24,472, of which approximately $23,472 was restricted and approximately $1,000 was unrestricted.

The restricted portion of the Gold and related account rights were pledged as collateral under the Company’s secured financing arrangements, including the Secured Convertible Debenture Purchase Agreement dated July 7, 2025 and the Guaranty and Security Agreement dated November 4, 2025.

Pursuant to the Securities Account Control Agreement dated November 4, 2025, GBI is required to comply with entitlement orders issued by YA II PN, LTD., acting as collateral agent (the “Collateral Agent”), and GBI will not follow Company instructions unless accompanied by the Collateral Agent’s express written consent. Upon receipt of a notice of sole control following an event of default, GBI would terminate the Company’s access to the securities account and take instructions solely from the Collateral Agent as the entitlement holder with respect to the account and property therein.

Pursuant to the Brink’s Bailee Agreement dated November 4, 2025, Brink’s acts solely as bailee of the Gold, acknowledges no property interest in the Gold, and any statutory or possessory liens are subordinated to the Collateral Agent’s first-priority security interest. Brink’s maximum liability amount under its arrangements with GBI is $125 million.

No entitlement orders or notices of sole control were issued during the three months ended March 31, 2026.

On December 29, 2025, management committed to a plan to sell the Gold in connection with the Company’s plan to resolve and repay its secured convertible debentures. The Company determined that all criteria for classification as held for sale under ASC 360-10-45-9 were met as of December 29, 2025. Accordingly, as of December 31, 2025, the Gold was classified as held for sale and measured at the lower of its carrying amount or fair value less cost to sell. Because fair value less cost to sell exceeded the carrying amount, no write-down was recorded prior to sale.

In February 2026, the Company transferred approximately $1,000 of unrestricted gold bullion at cost to Streamex Ltd. in connection with the establishment of the GLDY Token program. The transferred gold is included in “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet as of March 31, 2026 (see Note 9).

On February 5, 2026, the Company completed the sale of the remaining LBMA Good Delivery gold bullion previously classified as held for sale, with a carrying amount of approximately $23,472. The transaction was executed through the Company’s securities intermediary and resulted in cash proceeds of approximately $26,410. The Company recognized a gain of approximately $2,938 on the sale, which is included in “Realized gain on sale of gold” in other income (expense) in the unaudited condensed consolidated statements of operations. The proceeds were used to fund the repayment of the Yorkville Debentures (see Note 11).

As of March 31, 2026, no gold bullion classified as held for sale remained on the unaudited condensed consolidated balance sheet. Upon completion of the sale and settlement of the Convertible Debentures, all related security interests, liens, and custodial arrangements described above were terminated.

Gold Assets Held at Cost — Streamex Ltd. (VIE)

During the three months ended March 31, 2026, Streamex Ltd. (the Company’s consolidated VIE) acquired gold bullion consisting of (i) the approximately $1,000 of unrestricted gold transferred from the Company as described above, and (ii) approximately $14,225 of gold purchased directly by Streamex Ltd. with cash funded by the Company. As of March 31, 2026, the aggregate carrying amount of gold held by Streamex Ltd. was $15,225, classified as “Other assets held at cost – gold” within non-current assets on the unaudited condensed consolidated balance sheet. The gold is held to support the long-term GLDY Token program and related leasing activities and is accounted for as a long-lived tangible asset within the scope of ASC 360 (see Note 3).

As of March 31, 2026, the Company evaluated whether any events or changes in circumstances indicated that the carrying amount of its gold assets held at cost may not be recoverable. Based on this assessment, including consideration of gold market prices as of the balance sheet date, management concluded that no triggering events existed and no impairment charges were recorded during the three months ended March 31, 2026. See Note 9 for additional information regarding Streamex Ltd.

SUBSEQUENT EVENTS

3 Months Ended

Mar. 31, 2026

Subsequent Events [Abstract]

SUBSEQUENT EVENTS

NOTE 19 – SUBSEQUENT EVENTS

The Company has evaluated subsequent events from the balance sheet date through the date on which these unaudited condensed financial statements were issued. Other than as described in the notes below, the Company did not have any material subsequent events that impacted its unaudited condensed financial statements or disclosures.

GLDY Dividend

On April 17, 2026, the Board of Directors of Streamex Ltd., acting through GLDY ServiceCo, LLC as servicer, declared a scrip dividend of 0.000085 ounces of gold per GLDY Token for the month of March 2026, payable on April 17, 2026 to tokenholders of record as of that date. The dividend was funded by gold lease income earned on Streamex Ltd.’s gold holdings during March 2026 and was paid in the form of additional fractional GLDY Tokens. Each GLDY Token continues to represent one troy ounce of gold on a 1:1 basis, as confirmed by the third-party fund administrator. The noncontrolling interest holders’ share of the dividend was not material.

Appointment of Director and Equity Awards

On April 28, 2026, the Board appointed the Company’s Chief Investment Officer (“CIO”), to serve as a non-independent director of the Board for a term expiring at the Company’s 2026 annual meeting of stockholders or until his successor is duly elected and qualified, or until the earlier of his death, resignation or removal.

In connection with the CIO’s amended employment agreement effective April 6, 2026, the Board granted the CIO 1,250,000 RSUs and a special incentive award of 1,000,000 RSUs. Both awards vest in sixteen equal quarterly installments commencing July 1, 2026, subject to continued service, and become fully vested upon a protected termination, a change in control, or the termination.

Amended Employment Agreements and Equity Awards

On May 1, 2026, the Company entered into amended and restated employment agreements with the Company’s Chief Executive Officer (“CEO”) and the Company’s Interim Executive Chairman (“Interim Chairman”).

In connection with the amended agreements, the Board granted each of the CEO and Interim Chairman 1,500,000 PSUs for shares of the Company’s common stock, divided into five equal tranches of 300,000 shares each. Each tranche vests upon the Company’s cumulative sales of GLDY reaching the following milestones: (i) $250,000,000; (ii) $500,000,000; (iii) $1,000,000,000; (iv) $2,000,000,000; and (v) $3,000,000,000. Cumulative GLDY sales are measured in good faith by the Company and certified by the Compensation Committee. Vesting is subject to continued employment, except that the awards become fully vested upon a protected termination or a change in control. Any tranche that has not vested on or before the tenth anniversary of the effective date shall be forfeited.

Equity Transactions

Between April 1, 2026 and May 14, 2026, an aggregate of 5,890,148 Exchangeable Shares were converted into the same number of common stock by holders of the Exchangeable Shares.

Between April 1, 2026 and May 14, 2026, the Company issued 1,157,973 shares of common stock for vested restricted stock units, of which 723,611 shares were issued to related parties, including certain executive officers and directors of the Company.

On April 10, 2026, the Company entered into an Advisory & Consulting Agreement with a third-party consultant. In connection with the agreement, the Company granted an RSU award for 100,000 shares of the Company’s common stock, with 50,000 RSUs vesting and issued on the effective date and the remaining 50,000 RSUs vesting in two installments on the six-month and twelve-month anniversaries of the vesting commencement date, subject to continued service.

On April 6, 2026, the Company entered into a Consulting Agreement with a third-party consultant. In connection with the agreement, the Company granted an RSU award for 155,000 shares of the Company’s common stock that were vested and issued on April 29, 2026.

In May 2026, the Company rescinded a previously approved equity compensation arrangement with the Company’s General Counsel covering 700,000 shares of common stock. As part of this rescission, the shares were cancelled and the arrangement was terminated with no further equity compensation obligations.

PROPERTY AND EQUIPMENT (Tables)

3 Months Ended

Mar. 31, 2026

Property, Plant, and Equipment [Abstract]

SCHEDULE OF PROPERTY AND EQUIPMENT

Property and equipment as of March 31, 2026, and December 31, 2025 is summarized as follows:

SCHEDULE OF PROPERTY AND EQUIPMENT

	March 31,			December 31,
	2026			2025
Computer equipment	$	531		$	531
Furniture and fixtures		109			109
Testing/Demo equipment		312			312
Leasehold improvements		84			84
Total		1,036			1,036
Less accumulated depreciation		(1,024	)		(1,011	)
Property and equipment, net	$	12		$	25

BUSINESS ACQUISITION (Details Narrative) - USD ($)

3 Months Ended

12 Months Ended

Dec. 09, 2025

Nov. 04, 2025

May 28, 2025

Mar. 31, 2026

Dec. 31, 2025

Business Combination [Line Items]

Number of shares issued

109,070,079

Exchangeable shares issued, value

$ 105,498,000

Acquisition-related costs

$ 5,900,000

Deferred tax liability

$ 12,588,000

Federal and provincial rate

26.50%

Finite lived intangible assets

$ 47,880,000

47,880,000

1.00%

40.50%

$ 70,435,000

Business Combination [Line Items]

Finite lived intangible assets

$ 5,100,000

5,100,000

^[1]

5,100,000

^[1]

Estimated useful lives

10 years

Technology-Based Intangible Assets [Member]

Business Combination [Line Items]

Estimated useful lives

8 years

Securitization Platform [Member]

Business Combination [Line Items]

Finite lived intangible assets

$ 31,100,000

Blockchain Integration [Member]

Business Combination [Line Items]

Finite lived intangible assets

8,900,000

Legal and Compliance Frame Work [Member]

Business Combination [Line Items]

Finite lived intangible assets

$ 2,400,000

^[1]

$ 2,400,000

^[1]

Share Purchase Agreement [Member]

Business Combination [Line Items]

Number of shares issued

109,070,079

Exchangeable shares per purchased share

$ 2.046862

Number of shares issuance for acquisitions

12,671,297

Streamex Exchange Corporation [Member]

Business Combination [Line Items]

Business acquisition, date

May 28, 2025

Third party Consultants [Member]

Business Combination [Line Items]

Number of shares issuance for acquisitions

824,052

Finders fee, value

$ 4,820

Third party Consultants [Member] | Common Stock [Member]

Business Combination [Line Items]

Business acquisition issuance of shares

200,000

Business acquisition issuance of shares, value

$ 1,010

[1]

Intangible assets acquired in connection with the Streamex Exchange acquisition were initially measured in Canadian dollars and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in exchange rates are reflected in the carrying amounts presented above and recorded in other comprehensive loss as part of the cumulative translation adjustment.

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Tables)

3 Months Ended

Mar. 31, 2026

Accumulated Other Comprehensive Income (Loss) [Line Items]

SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS

The following table presents information related to stock options as of March 31, 2026:

Options Outstanding						Options Exercisable
Exercise		Number of		Weighted Average Remaining Life		Exercisable Number of
Price		Options		In Years		Options
$	Under 9.99		2,900,000		8.6		2,900,000
$	10.00-19.99		15,000		7.1		15,000
$	20.00-49.99		3,000		3.0		3,000
$	50.00-69.99		3,000		3.8		3,000
			2,921,000		8.6		2,921,000

SCHEDULE OF OPTIONS GRANTED ASSUMPTIONS USING BLACK-SCHOLES OPTION

During the three months ended March 31, 2026, the Company granted options to purchase shares of its common stock, which were valued using the Black-Scholes option pricing model. The following assumptions were used to calculate the fair value of the options granted during the three months ended March 31, 2026:

Assumption	Value
Weighted average grant date fair value	$	3.08
Expected volatility		124.17	%
Risk-free interest rate		4.15	%
Expected dividend yield		0.00	%
Expected Term (in years)		5.0

SCHEDULE OF INFORMATION RELATED TO WARRANTS

The following table summarizes information with respect to outstanding warrants to purchase common stock of Streamex Corp. as of March 31, 2026:

Exercise Price		Number of Warrants		Expiration Date
$	0.3000		11,982	Nov-28
	0.9547		577,916	Sep-28
	3.3640		117,828	Jul-29
	4.0660		25,000	Nov-32
	4.4550		107,483	Jun-28
	4.4660		5,580	Apr-29
	4.6626		49,550	Mar-29
	4.9252		71,593	Mar-29
	4.9290		99,243	Jul-28
	5.1358		83,270	Jul-28
	7.1810		9,846	Jul-28
	7.5020		21,369	Aug-28
	7.9630		21,709	Jun-27
	9.0000		84,390	Jan-29
	9.5960		19,118	Aug-28
	10.0992		51,705	Sep-28
	10.2600		84,296	Sep-28
	10.4678		40,417	Oct-28
	11.3000		96,198	Nov-28
	13.2800		12,500	Jul-26
	48.0000		56,892	Nov-27
	61.6000		11,982	Nov-28
			1,647,885

SUMMARY OF WARRANT ACTIVITY

A summary of the warrant activity for three months ended March 31, 2026 is as follows:

SCHEDULE OF WARRANT ACTIVITY

	Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at January 1, 2026		1,735,869		$	6.94		2.8	$	1,414,626
Issued		-			-		-
Forfeited/expired		-			-		-		-
Exercised		(87,984	)		0.95		-		-
Outstanding at March 31, 2026		1,647,885		$	7.26		2.6	$	111,231

Vested and expected to vest at March 31, 2026		1,647,885		$	7.26		2.6	$	111,231
Exercisable at March 31, 2026		1,647,885		$	7.26		2.6	$	111,231

SCHEDULE OF RESTRICTED STOCK UNITS GRANTS

Grant Date	Recipient	RSUs Granted		Vesting Terms	GDFV¹
1/1/2026	Third-party consultant		250,000	25,000 immediately; remainder quarterly	$	758
1/8/2026	Interim Executive Chairman		100,000	4 equal quarterly installments over 1 year	$	321
1/8/2026	Chief Executive Officer		1,000,000	100,000 on May 15, 2026; 900,000 in 16 quarterly installments over 4 years	$	3,210
1/27/2026	Third-party consultant		125,000	16 quarterly installments over 4 years	$	456
2/1/2026	Third-party consultant		500,000	300,000 immediately; 200,000 in 4 quarterly installments over 12 months	$	1,790
3/3/2026	Third-party consultant		425,000	212,500 immediately; 125,000 on Jun 3; 87,500 on Sep 3, 2026	$	876
3/16/2026	Third-party consultant		65,000	5,000 immediately; remainder monthly	$	119
3/16/2026	Chief Financial Officer		500,000	16 quarterly installments over 4 years	$	915
			2,965,000		$	8,445

(1)

Grant-date fair value (“GDFV”)

The table above includes only RSU grants issued during the three months ended March 31, 2026 that were subject to vesting conditions extending beyond the grant date. During the same period, the Company also granted an aggregate of 5,903,316 RSUs that vested immediately upon grant and are therefore excluded from this table. The total RSUs granted during the three months ended March 31, 2026 were 8,868,316, as reflected in the RSU activity table above.

SCHEDULE OF ESTIMATED GRANT DATE FAIR VALUE

Assumption	Value
Grant-date stock price		$3.58
Stock price milestones		$5.00 – $12.00
Expected volatility		152.9%
Risk-free interest rate		3.72%
Expected dividend yield		0.00%
Derived service periods (range)		3.43 – 7.41 years

SCHEDULE OF RELATED TO WARRANTS

The following table presents information related to warrants (ViralClear) at March 31, 2026:

SCHEDULE OF RELATED TO WARRANTS

Exercise		Number		Expiration
Price		Outstanding		Date
$	5.00		473,772		November 2027

SCHEDULE OF OUTSTANDING TO WARRANTS

The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at March 31, 2026:

SCHEDULE OF OUTSTANDING TO WARRANTS

Exercise		Number		Expiration
Price		Outstanding		Date
$	1.00		130,500		June-July 2028

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

SUMMARY OF WARRANT ACTIVITY

A summary of the warrant activity for three months ended March 31, 2026 is as follows:

SUMMARY OF WARRANT ACTIVITY

					Weighted-Average
					Remaining
			Weighted-Average		Contractual
	Shares		Exercise Price		Term
Outstanding at January 1, 2026		473,772	$	5.00		1.9
Forfeited/expired		-		-		-
Outstanding at March 31, 2026		473,772	$	5.00		1.6
Exercisable at March 31, 2026		473,772	$	5.00		1.6

Viral Clear Pharmaceuticals Inc [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

SCHEDULE OF RESTRICTED STOCK ACTIVITY

The following table summarizes the restricted stock activity for the three months ended March 31, 2026:

SCHEDULE OF RESTRICTED STOCK ACTIVITY

	Number of Shares			Weighted-Average Grant Date Fair Value Per Share
Restricted shares issued as of January 1, 2026		2,037,500		$	5.36
Granted		8,868,316		$	2.91
Vested and issued		(6,123,941	)	$	3.01
Forfeited		(198,500	)	$	3.21
Total		4,583,375		$	3.86
Comprised of:
Vested restricted shares as of March 31, 2026		301,500		$	3.21
Unvested restricted shares as of March 31, 2026		4,281,875		$	3.90

Viral Clear [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

SCHEDULE OF NON VESTED RESTRICTED ACTIVITY

The following table summarizes the restricted stock activity for the three months ended March 31, 2026:

Restricted shares outstanding at January 1, 2026:			678,679
Forfeited			-
Total restricted shares outstanding at March 31, 2026:			678,679

Comprised of:
Vested restricted shares as of March 31, 2026			678,679
Unvested restricted shares as of March 31, 2026			-
Total			678,679

Equity Option [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

SCHEDULE OF STOCK OPTION ACTIVITY

A summary of the stock option activity and related information for the Plan for the three months ended March 31, 2026 is as follows:

SCHEDULE OF STOCK OPTION ACTIVITY

	Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at January 1, 2026		2,736,000		$	0.78		8.7	$	6,744,540
Issued		250,000		$	3.21		9.8
Forfeited/expired		(65,000	)	$	5.01
Outstanding at March 31, 2026		2,921,000		$	0.89		8.6	$	1,709,540
Exercisable at March 31, 2026		2,921,000		$	0.89		8.6	$	1,709,540

Performance Shares [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

SCHEDULE OF NON VESTED RESTRICTED ACTIVITY

The following table summarizes PSU activity for the three months ended March 31, 2026:

	PSUs – Stock Price		PSUs - AUM		Total PSUs
Nonvested as of December 31, 2025		-		-		-
Granted		500,000		1,000,000		1,500,000
Vested and issued		-		-		-
Forfeited		-		-		-
Nonvested as of March 31, 2026		500,000		1,000,000		1,500,000

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Details Narrative) - USD ($) $ in Thousands	Mar. 31, 2026	Feb. 06, 2026	Dec. 31, 2025
Assets	$ 173,317		$ 187,543
Intangible assets and goodwill	111,931
Cash	4,907
Sales tax receivable	59		51
Prepaid expenses and other assets	33
Cash	6,859	$ 38,903	$ 20,316
Consolidated Entity, Excluding Consolidated VIE [Member]
Cash	60
UNITED STATES
Assets	$ 56,387
Consolidated asset percentage	33.00%
Cash	$ 1,952
CANADA
Assets	$ 116,930
Consolidated asset percentage	67.00%
Cash	$ 4,907

SEGMENT REPORTING (Tables)

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

SCHEDULE OF SEGMENT REPORTING

Information concerning the operations of the Company’s reportable segments is as follows:

SCHEDULE OF SEGMENT REPORTING

	2026			2025
	For the Three Months Ended March 31,
	2026			2025

Revenues	$	-		$	-
Less Segment expenses:
Research and development		-			6
General and administrative		8,884			883
General and administrative - stock-based compensation expenses		25,370			2,074
Depreciation and amortization		1,492			21
Total operating and segment expense		(35,746	)		(2,984	)
Plus:
Interest expense, net		(12,195	)		-
Realized gain on sale of gold		2,938			-
Realized gain on marketable securities		484			-
Change in fair value of marketable securities		(134	)		-
Change in fair value of embedded derivative		497			-
Realized loss on extinguishment of convertible debenture		(3,057	)		-
Realized loss on investment		(119	)		-
Gain on settlement and forgiveness of debt		-			199
Other income (expense), net		73			(15	)
Total other income (expense)		(11,513	)		184
Income taxes (benefit)		(565	)		-
Segment Net Loss	$	(46,694	)	$	(2,800	)
Non-controlling interest		1			(12	)
Net loss attributable to Streamex Corp.	$	(46,693	)	$	(2,812	)

- Definition

Tabular disclosure of segment reporting. Includes, but is not limited to, reconciliation of reportable segment amount to corresponding consolidated total.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 2: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26A

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 25
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-25

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

+ Details

NON-CONTROLLING INTEREST (Tables)

3 Months Ended

Mar. 31, 2026

Noncontrolling Interest [Abstract]

SCHEDULE OF NON-CONTROLLING INTEREST

Net loss attributable to the non-controlling interest for the three months ended March 31, 2026:

SCHEDULE OF NON-CONTROLLING INTEREST

	ViralClear Pharmaceuticals, Inc.			BioSig AI Sciences, Inc.			Streamex Ltd			Total
Net Income (loss)	$	-*		$	-		$	(155	)	$	(155	)
Noncontrolling interest’s weighted-average ownership percentage		30.0	%		16.0	%		0.2	%		0.01	%
Net income (loss) attributable to non-controlling interest	$	-*		$	-		$	(1	)	$	(1	)

Net loss attributable to the non-controlling interest for the three months ended March 31, 2025:

	ViralClear Pharmaceuticals, Inc.			BioSig AI Sciences, Inc.			Streamex Ltd			Total
Net loss	$	-*		$	75		$	-		$	75
Noncontrolling interest’s weighted-average ownership percentage		32	%		16	%		-	%		16	%
Net loss attributable to non-controlling interest	$	-*		$	12		$	-		$	12

Less than $0.5 thousand

SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2026:

	ViralClear Pharmaceuticals, Inc.			BioSig AI Sciences, Inc.		Streamex Ltd			Total
Balance, January 1, 2026	$	(171	)	$	203	$	-		$	32
Issuance of equity to noncontrolling interest holders		-			-		225			225
Net income (loss) attributable to non-controlling interest		-			-		(1	)		(1	)
Balance, March 31, 2026	$	(171	)	$	203	$	224		$	256

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2025:

	ViralClear Pharmaceuticals, Inc.			BioSig AI Sciences, Inc.		Streamex Ltd		Total
Balance, January 1, 2025	$	(171	)	$	188	$	-	$	17
Net income (loss) attributable to non-controlling interest		-			12		-		12
Balance, March 31, 2025	$	(171	)	$	200	$	-	$	29

NON-CONTROLLING INTEREST (Details Narrative)	3 Months Ended
NON-CONTROLLING INTEREST (Details Narrative)	Mar. 31, 2026	Dec. 31, 2025
Related Party [Member]
Variable interest percentage	1.50%
Viral Clear Pharmaceuticals Inc [Member]
Majority interest	70.00%	70.00%
BioSig AI Sciences, Inc. [Member]
Majority interest	84.00%	84.00%

BUSINESS ACQUISITION

3 Months Ended

Mar. 31, 2026

Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]

BUSINESS ACQUISITION

NOTE 4 – BUSINESS ACQUISITION

Streamex Exchange Corporation

Transaction Overview

On May 28, 2025, the Company completed the acquisition of Streamex Exchange, a software development company based in Vancouver, British Columbia, specializing in digital tools for commodity trading and finance.

The acquisition was effected pursuant to the Share Purchase Agreement dated May 23, 2025, as amended on May 27, 2025, by and among the Company, its wholly-owned subsidiaries ExchangeCo and Callco, the Streamex Exchange Shareholders, and 1540873 B.C. Ltd., as trustee under the Exchange Rights Agreement.

Under the terms of the Share Purchase Agreement, ExchangeCo acquired all of the issued and outstanding shares of Streamex Exchange (the “Purchased Shares”) in exchange for 109,070,079 Exchangeable Shares of ExchangeCo, issued at a ratio of 2.046862 Exchangeable Shares per Purchased Share. The Exchangeable Shares are exchangeable on a one-for-one basis for shares of the Company’s common stock, subject to certain adjustments and conditions described below.

The purpose of the Acquisition was to enhance shareholder value by combining with a privately held operating company and positioning the combined entity for future growth with expansion into digital commodity trading and blockchain-based financial technologies. The acquisition was undertaken to expand the Company’s technology platform into digital commodity trading and blockchain-based financial infrastructure and to obtain the assembled workforce, intellectual property, and regulatory capabilities of Streamex Exchange.

In connection with the transaction, the Company evaluated the accounting under ASC 805, Business Combinations, and ASC 810, Consolidation. The Company concluded the acquired set met the definition of a business. In making this determination, the Company considered the concentration test in ASC 805 and determined that substantially all of the fair value of the gross assets acquired was not concentrated in a single identifiable asset or group of similar identifiable assets. The Company also evaluated whether the acquiree is a variable interest entity (“VIE”) and concluded Streamex Exchange is a VIE because, among other factors, it lacked sufficient equity at risk to finance its activities without additional subordinated financial support and the equity holders, as a group, did not have substantive power to direct the activities that most significantly impact economic performance at the acquisition date.

The Company concluded it is the primary beneficiary because it has both (i) the power to direct the activities that most significantly impact Streamex’s economic performance through governance rights in place at closing and (ii) the obligation to absorb losses or the right to receive benefits that could potentially be significant. Accordingly, the transaction is accounted for as a business combination with the Company as the accounting acquirer, and Streamex Exchange has been consolidated in the Company’s financial statements from the acquisition date.

Shareholder Approval and Contingent Features

Initially, the Exchangeable Shares were not exchangeable into more than 19.99% of the Company’s outstanding common stock on a pre-transaction basis, in accordance with Nasdaq listing rules. Following the closing, the Company sought stockholder approval for certain matters related to the transaction, including the issuance of shares of common stock exchangeable for Exchangeable Shares, the issuance of shares underlying the Convertible Debentures, increases to the authorized share count and the 2023 Long-Term Incentive Plan, and amendments to the Company’s Amended and Restated Certificate of Incorporation. At the special meeting of stockholders held on September 5, 2025, all proposals except the issuance of shares exchangeable for Exchangeable Shares (Proposal A) were approved. Proposal A was subsequently approved on November 4, 2025.

Following stockholder approval of Proposal A on November 4, 2025, and subject to the terms of the Exchange Rights Agreement, the holders of Exchangeable Shares are entitled to exchange such shares for an aggregate of 109,070,079 shares of the Company’s common stock representing up to 75% of the Company’s fully diluted common stock as of the Share Purchase Agreement date.

Consideration Transferred

The fair value of the consideration transferred was $105,498, consisting entirely of Exchangeable Shares issued by ExchangeCo. Due to the lack of an active market for the Exchangeable Shares and the contingent nature of their conversion, a fundamentals-based valuation approach was used to estimate the fair value of the consideration. The contingent consideration related to the potential adjustment of the Exchange Ratio from 1.0 to 1.25—triggered if shareholder approval is not obtained within six months following the closing date—was not included in the purchase consideration as of May 28, 2025. As stockholder approval was obtained on November 4, 2025, within six months of the closing date, the exchange ratio adjustment was not triggered, and no additional consideration was required. For an overview of the Company’s derivative financial instruments and related disclosures required by ASC 815, see Note 11, Convertible Debentures and Related Derivative Instruments. See Note 12, Fair Value Measurements and Note 13, Stockholders’ Equity.

On November 4, 2025, the Company received shareholder approval for the issuance of our shares of common stock exchangeable for Exchangeable Shares and one share of Special Voting Preferred Stock in connection with the Share Purchase Agreement. As a result, the conversion cap was removed, and Streamex Exchange shareholders may convert their Exchangeable Shares into the Company’s common stock. Concurrently, the derivative liability associated with the Exchangeable Shares was reclassified to permanent equity. As a result of the reclassification, the Exchangeable Shares are classified as permanent equity and are presented within stockholders’ equity in the consolidated balance sheet. No derivative liability related to the Exchangeable Shares remained outstanding as of March 31, 2026 or December 31, 2025. Although the Exchangeable Shares were reclassified to permanent equity upon stockholder approval on November 4, 2025, the consideration transferred for purposes of the acquisition date purchase price allocation reflects the fair value of the Exchangeable Shares as of May 28, 2025.

In connection with the acquisition of Streamex Exchange, the Company incurred total acquisition-related costs of $5.9 million during the year ended December 31, 2025. These costs primarily consisted of legal, accounting, and consulting fees directly attributable to the transaction. Included in this amount was the issuance of 200,000 shares of the Company’s common stock to a third-party consultant, valued at $1,010 based on the grant-date fair value and the expected issuance of 824,052 shares of the Company’s common stock to third party consultants in connection with a finders fee, valued at $4,820. These costs were expensed as incurred and are reflected in general and administrative expenses in the Unaudited Condensed Consolidated Statements of Operations.

Purchase Price Allocation

The Company applied the acquisition method of accounting in accordance with ASC 805, Business Combinations (“ASC 805”) and recognized assets acquired and liabilities assumed at their estimated fair value as of the date of acquisition, with the excess purchase consideration recorded to goodwill. During the three months ended March 31, 2026, the Company completed its assessment of the fair values of the assets acquired and liabilities assumed in connection with the acquisition of Streamex Exchange. No measurement period adjustments were recorded during the three months ended March 31, 2026.

The Acquisition was recorded as a business combination based on a valuation of assets acquired and liabilities assumed at their acquisition date fair values using unobservable inputs that are supported by little or no market activity and are significant to their fair value of the assets and liabilities (“Level 3” inputs). Goodwill represents the excess of the purchase price consideration over the valuation of the net assets acquired.

The final allocation of the purchase consideration is as follows:

Amount Recognized as of the Acquisition Date (In Thousands)
Assets acquired
Cash	$	366
Due from related party		11
Sales tax receivable		14
Prepaid expenses		22
Trade name		5,100
Developed technology		40,000
Legal and compliance framework		2,400
Goodwill		70,435
Total assets acquired	$	118,348
Liabilities assumed
Accounts payable and accrued expenses	$	(262	)
Deferred tax liability		(12,588	)
Total liabilities assumed	$	(12,850	)
Net assets acquired		105,498

Deferred tax liability

In connection with the acquisition of Streamex Exchange, the transaction was structured as a stock acquisition for both U.S. and Canadian tax purposes. No election was made under IRC §338(g); therefore, no step-up in the tax basis of the acquired assets was obtained in either jurisdiction. The purchase price allocation created taxable temporary differences related to identifiable intangible assets, resulting in a deferred tax liability of approximately $12,588, measured using the enacted combined Canadian federal and provincial rate of 26.5%. Because these deferred tax liabilities arise in a separate foreign jurisdiction, they cannot offset deferred tax assets of the U.S. parent. The corresponding increase in goodwill was recognized as part of purchase accounting.

Intangible Assets

The Company identified the following finite-lived intangible assets:

	●	Trade Name: Valued at $5,100 using the relief-from-royalty method, applying a 1.0% royalty rate and a 40.5% discount rate. The trade name is expected to be utilized over a 10-year period and is amortized accordingly.

	●	Developed Technology

		Comprised of two distinct components, both valued using the multi-period excess earnings method (MPEEM) and amortized over 8 years:

	●	Securitization Platform: Valued at $31,100, representing proprietary protocols and infrastructure enabling the tokenization of real-world assets and integration with decentralized finance platforms.

	●	Blockchain Integration: Valued at $8,900, reflecting proprietary systems facilitating token creation and secondary market trading through blockchain-based platforms.

●

Legal and Compliance Framework: Valued at $2,400 using the cost approach, based on the estimated cost to recreate the regulatory and legal infrastructure necessary for operations. The asset has a useful life of 7 years and is amortized accordingly. The legal and compliance framework supports the Company’s ability to operate in regulated jurisdictions and reduce legal and regulatory risk exposure.

Goodwill

Goodwill of $70,435 represents the excess of the purchase consideration over the fair value of net assets acquired and was recognized in connection with the acquisition. None of the goodwill is expected to be deductible for tax purposes. The goodwill is assigned to the consolidated reporting unit, as the Company operates as a single segment. The goodwill primarily represents expected synergies, assembled workforce, and future growth potential. No goodwill arose from step acquisitions or noncontrolling interests.

- Definition

The entire disclosure for business combination.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 38
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-38

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 46
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-46

Reference 4: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 43
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-43

Reference 5: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 45
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-45

Reference 6: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 7: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 29
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-29

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-4

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 40
-Name Accounting Standards Codification
-Section 45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479326/805-40-45-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-30/tableOfContent

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-20/tableOfContent

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-7

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-5

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/805-10/tableOfContent

+ Details

ACCOUNTS PAYABLE AND ACCRUED EXPENSES (Tables)

3 Months Ended

Mar. 31, 2026

Payables and Accruals [Abstract]

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE

Accounts payable and accrued expenses as of March 31, 2026, and December 31, 2025, consist of the following:

	March 31,		December 31,
	2026		2025
Accrued accounting and legal	$	725	$	705
Accrued consulting		564		406
Accrued interest		-		200
Accrued research and development expenses		167		169
Accrued office and other		41		38
Accrued insurance premium financing⁽¹⁾		370		916
Accrued payroll⁽²⁾		1,180		512
Other accrued expenses		132		6
	$	3,179	$	2,952

	(1)	On August 27, 2025, the Company entered into a premium finance agreement for the policy period beginning August 3, 2025. The total premium was $2,172, of which $544 was paid as a down payment and $1,600 was financed. The agreement includes a finance charge of $51, resulting in total payments of $1,700 payable in nine monthly installments of $187 through May 2026 at an annual percentage rate of 7.48%. The financing obligation is secured by unearned premiums under the financed policies. As of March 31, 2026, the amount included in prepaid insurance is approximately $570 and AFCO loan payable of approximately $370. Prepaid insurance is amortized over the policy term, and the financing liability is reduced as payments are made. Interest expense is recognized using the effective interest method.

	(2)	Includes approximately $779 related to severance and other separation-related obligations associated with the Company’s former Chief Financial Officer pursuant to a Separation and General Release Agreement entered into in March 2026. The accrued amount includes cash severance, pro rata bonus components, and other related obligations expected to be paid in accordance with the terms of the agreement.

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE (Details) - shares	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Totals	11,087,105	9,788,324
Share-Based Payment Arrangement, Option [Member]
Totals	2,921,000	2,486,000
Performance Based Restricted Stock Unit [Member]
Totals	1,500,000
Warrant [Member]
Totals	1,647,885	5,577,260
Restricted Stock [Member]
Totals	4,583,375	1,160,830
Series C Preferred Stock [Member]
Totals	434,845	564,234

SCHEDULE OF FUTURE AMORTIZATION EXPENSE OF INTANGIBLE ASSETS (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Dec. 31, 2025
Intangible Asset, Goodwill and Other [Abstract]
Remainder 2026	$ 4,362
2027	5,816
2028	5,816
2029	5,816
2030	5,816
Thereafter	14,792
Intangible assets, net	$ 42,418	$ 44,639

GOODWILL AND INTANGIBLE ASSETS (Tables)

3 Months Ended

Mar. 31, 2026

Intangible Asset, Goodwill and Other [Abstract]

SCHEDULE OF CARRYING AMOUNT OF GOODWILL

The following table shows the changes in the carrying amount of goodwill for the period:

SCHEDULE OF CARRYING AMOUNT OF GOODWILL

Goodwill as of December 31, 2025 (1)	$	70,984
Acquisition		-
Impairment		-
Foreign currency translation adjustment		(1,226	)
Goodwill as of March 31, 2026	$	69,758

Related to the acquisition of the Streamex Exchange. See Note 4 for more details. Goodwill was initially measured in the functional currency of Streamex Exchange and translated into U.S. dollars using the exchange rate in effect on the acquisition date. Subsequent changes in foreign exchange rates are reflected in the cumulative translation adjustment within other comprehensive loss.

SCHEDULE OF INTANGIBLE ASSETS

The following summarizes the Company’s intangible assets as of March 31, 2026 and December 31, 2025:

SCHEDULE OF INTANGIBLE ASSETS

	March 31,			December 31,
	2026			2025
Trade name (1)	$	5,100		$	5,100
Developed technology (1)		40,000			40,000
Legal and compliance framework (1)		2,400			2,400
Patents		380			380
Total		47,880			47,880
Foreign currency translation adjustment		(456	)		371
Accumulated amortization:
Trade name		(425	)		(303	)
Developed technology		(4,162	)		(2,975	)
Legal and compliance framework		(285	)		(204	)
Patents		(134	)		(130	)
Total accumulated amortization		(5,006	)		(3,612	)
Intangible assets, net	$	42,418		$	44,639

SCHEDULE OF FUTURE AMORTIZATION EXPENSE OF INTANGIBLE ASSETS

Expected future amortization expense of intangible assets as of March 31, 2026, is as follows:


Remainder 2026	$	4,362
2027		5,816
2028		5,816
2029		5,816
2030		5,816
Thereafter		14,792
Total	$	42,418

- Definition

Tabular disclosure of goodwill.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 55
-Paragraph 24
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482548/350-20-55-24

Reference 3: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 4: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 5: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 6: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 7: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 9: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 11: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1

Reference 12: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-1A

+ Details

FAIR VALUE MEASUREMENTS (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
	Jan. 31, 2026	Mar. 31, 2026	Mar. 31, 2025
Fair Value Disclosures [Abstract]
Embedded derivative gain		$ 497
Embedded derivative liability		1,203
Embedded derivative loss		443
Gross proceeds	$ 10,190	$ 10,190
Other income	$ 484

SCHEDULE OF OPTIONS GRANTED ASSUMPTIONS USING BLACK-SCHOLES OPTION (Details)	3 Months Ended
	Mar. 31, 2026
Measurement Input, Share Price [Member]
Business Combination [Line Items]
Derivative liability	3.08
Measurement Input, Price Volatility [Member] \| Minimum [Member]
Business Combination [Line Items]
Derivative liability	124.17
Measurement Input, Risk Free Interest Rate [Member]
Business Combination [Line Items]
Derivative liability	4.15
Measurement Input, Expected Dividend Rate [Member]
Business Combination [Line Items]
Derivative liability	0.00
Measurement Input, Expected Term [Member]
Business Combination [Line Items]
Derivative liability, measurement input, expected life	5 years

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-8

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 350
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482573/350-20-50-4

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479303/805-10-55-47

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-5

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 10: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-3

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4

Reference 22: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 4A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-4A

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 4
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-4

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479581/805-30-50-1

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (b)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479907/805-20-50-1

Reference 37: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(4)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 41: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

Reference 42: http://www.xbrl.org/2003/role/disclosureRef
-Topic 805
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479328/805-10-50-2

+ Details

RELATED PARTY TRANSACTIONS

3 Months Ended

Mar. 31, 2026

RELATED PARTY TRANSACTIONS

NOTE 18– RELATED PARTY TRANSACTIONS

Accounts payable and accrued expenses as of March 31, 2026 include $907 due to related parties, compared to $66 as of December 31, 2025. These amounts primarily relate to executives and board compensation, severance, and reimbursements.

During the three months ended March 31, 2026, two officers of the Company subscribed for GLDY Tokens issued by Streamex Ltd. (the Company’s consolidated VIE): (i) the Company’s Chief Investment Officer, subscribed for approximately $200 of GLDY Tokens, and (ii) the Company’s General Counsel, subscribed for approximately $25 of GLDY Tokens. Both subscriptions were made on the same terms and at the same per-token price as the Company’s own subscriptions pursuant to the GLDY Subscription Agreement. As of March 31, 2026, the officers’ combined GLDY Token holdings represented approximately 1.5% of total outstanding tokens. See Note 9, Streamex Ltd. (VIE), for additional information.

- Definition

The entire disclosure for related party transactions. Examples of related party transactions include transactions between (a) a parent company and its subsidiary; (b) subsidiaries of a common parent; (c) and entity and its principal owners; and (d) affiliates.

+ References

+ Details

LIQUIDITY (Details Narrative) - USD ($) $ in Thousands	1 Months Ended	3 Months Ended
LIQUIDITY (Details Narrative) - USD ($) $ in Thousands	Jan. 31, 2026	Mar. 31, 2026	Mar. 31, 2025
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Working capital deficit		$ 42,602
Cash		6,859
Net cash operating activities		10,179	$ 1,115
Net cash investing activities		1,500
Net cash financing activities		1,637	(4,700)
Secured debt		38,500
Net proceeds	$ 37,200	37,184
Marketable securities		10,100
Sale of trust assets		26,400
Cash payments		$ 38,500

SCHEDULE OF EXERCISE PRICE OF STOCK OPTIONS (Details) - $ / shares	3 Months Ended
	Mar. 31, 2026	Dec. 31, 2025
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number of Options Outstanding	2,921,000	2,736,000
Number of Options Outstanding Weighted Average Remaining Life	8 years 7 months 6 days
Number of Options Outstanding Options Exercisable	2,921,000
Options Under 9.99 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 9.99
Number of Options Outstanding	2,900,000
Number of Options Outstanding Weighted Average Remaining Life	8 years 7 months 6 days
Number of Options Outstanding Options Exercisable	2,900,000
Options 10.00 To 19.99 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 10.00
Number of Options Outstanding	15,000
Number of Options Outstanding Weighted Average Remaining Life	7 years 1 month 6 days
Number of Options Outstanding Options Exercisable	15,000
Options Outstanding, Exercise Price	$ 19.99
Options 20.00 To 49.99 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 20.00
Number of Options Outstanding	3,000
Number of Options Outstanding Weighted Average Remaining Life	3 years
Number of Options Outstanding Options Exercisable	3,000
Options Outstanding, Exercise Price	$ 49.99
Options 50.00 To 69.99 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Options Outstanding, Exercise Price	$ 50.00
Number of Options Outstanding	3,000
Number of Options Outstanding Weighted Average Remaining Life	3 years 9 months 18 days
Number of Options Outstanding Options Exercisable	3,000
Options Outstanding, Exercise Price	$ 69.99

MARKETABLE SECURITIES (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands			1 Months Ended	3 Months Ended		12 Months Ended
	Feb. 06, 2026	Dec. 09, 2025	Jan. 31, 2026	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025	Mar. 16, 2026	Feb. 26, 2026	Jan. 12, 2024
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Outstanding percentage				25.00%
Fair value of marketable securities				$ 23,766		$ 9,706		$ 23,900
Marketable securities cost				23,900
Unrealized loss				(134)
Dividend income				71
Issuance of shares	3,750,000
Share price							$ 3.00		$ 3.00
Gross proceeds				10,100
Realized gain				484
Empress Royalty Corp [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Unrealized gain or loss				0
Gross proceeds			$ 10,190
Realized gain			$ 484
Impairment charges				$ 0
Share Purchase Agreement [Member]
Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]
Outstanding percentage		9.90%
Issuance of shares acquired		12,671,297
Issuance of restricted shares		2,443,750
Investments		$ 10,533
Issuance of shares		2,443,750
Share price		$ 4.31
Fair value of investment						9,706
Unrealized gain or loss						$ (827)

CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS

3 Months Ended

Mar. 31, 2026

Debt Disclosure [Abstract]

CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS

NOTE 11 – CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS

On November 4, 2025 and December 17, 2025, the Company issued two tranches of senior secured convertible debentures to YA II PN, Ltd. (“Yorkville”) (collectively, the “Convertible Debentures”) with aggregate principal of $50,000 (each tranche with principal of $25,000). The Convertible Debentures were issued as part of the Company’s capital-raising strategy to fund operations and growth initiatives.

Each debenture was issued at a purchase price of 96% of principal, bore interest at 4.0% per annum (increasing to 18.0% upon an event of default), and had a contractual maturity date that was 24 months from issuance (November 4, 2027 and December 17, 2027, respectively).

The Convertible Debentures were secured by first-priority liens on substantially all assets of the Company and were guaranteed by certain subsidiaries. Upon settlement in February 2026, all related security interests and liens were released.

Conversion Features

Yorkville could convert all or any portion of the outstanding principal and accrued interest into shares of the Company’s common stock at a conversion price equal to the lower of:

(i) a fixed price of $6.016 per share, subject to a one-time downward-only reset following registration effectiveness, and

(ii) 97% of the lowest daily volume-weighted average price (“VWAP”) during the three trading days immediately preceding conversion, subject to a $4.00 per share floor price, in each case subject to customary anti-dilution adjustments.

Conversions were also subject to a beneficial ownership limitation (generally 4.99%) and an exchange cap tied to Nasdaq rules, unless stockholder approval was obtained or the limitation was otherwise waived pursuant to the debenture terms.

If fully converted at the $4.00 floor price, the $50,000 principal amount of the Convertible Debentures would have been convertible into a maximum of 12,500,000 shares of the Company’s common stock, exclusive of any shares issuable for accrued interest or premiums. The Company did not register any shares for issuance under the Convertible Debentures and elected to utilize its optional cash settlement provisions in February 2026.

Embedded Derivative Liability – Conversion Option

The Company determined that the holder’s optional conversion feature requires bifurcation as an embedded derivative under ASC 815, Derivatives and Hedging, because (i) the economic characteristics of the conversion feature were not clearly and closely related to the host debt instrument and (ii) the conversion feature did not qualify for equity classification due to its variable conversion pricing mechanics, including VWAP-based pricing, floor price provisions, and reset features.

Accordingly, the embedded conversion option was accounted for separately as a derivative liability measured at fair value, with changes in fair value recognized in earnings each reporting period. At issuance, the Company allocated proceeds between the host debt and the embedded derivative based on relative fair value, with the derivative recorded as a liability and a corresponding amount recorded as a debt discount on the host debenture. This debt discount was amortized to interest expense using the effective interest method over the estimated term of the debenture. As of March 31, 2026, the embedded derivative liability was fully settled and no balance remained outstanding. See Note 12, Fair Value Measurements, for information regarding the valuation methodology, significant unobservable inputs, sensitivity considerations, changes in fair value, the tabular presentation of gains and losses on derivative instruments recognized in earnings as required by ASC 815, and the Level 3 rollforward of the embedded derivative liability.

The Company does not designate any derivative instruments as hedging instruments for accounting purposes and does not apply hedge accounting.

Debt Carrying Amount and Interest Expense

As of March 31, 2026, the carrying value of the Convertible Debentures, net of unamortized original issue discount, debt issuance costs, and bifurcation-related discounts, was $0 on a combined basis.

Interest expense recognized for the three months ended March 31, 2026 includes stated coupon interest and amortization of debt discounts and issuance costs under the effective interest method. For the three months ended March 31, 2026, the Company recognized total interest expense of approximately $12,182 related to the Convertible Debentures, consisting of approximately $203 of contractual interest and approximately $11,979 of non-cash interest expense from the amortization of discounts and issuance costs. Interest expense is included in “Interest expense, net” in the unaudited condensed consolidated statements of operations.

The effective interest rate on the Convertible Debentures substantially exceeded the 4.0% stated coupon rate. On December 29, 2025, management committed to a plan to settle the Convertible Debentures in early 2026, which constituted a change in the estimated life of the instruments. The Company prospectively recalculated the effective interest rates based on the revised expected settlement date of February 6, 2026. The resulting effective interest rates for the November 4, 2025 tranche and the December 17, 2025 tranche were approximately 393.7% and 228.9%, respectively, reflecting the accelerated amortization of unamortized discounts and issuance costs over a significantly shortened expected term. These revised rates were applied from December 29, 2025 through the settlement date of February 6, 2026, and are the basis for the non-cash interest expense from the accelerated amortization of discounts and issuance costs described above. Upon settlement, all remaining unamortized discounts and issuance costs were fully amortized and the net carrying value of the Convertible Debentures was reduced to zero. Had the Convertible Debentures been held to their contractual maturity dates of November 4, 2027 and December 17, 2027, respectively, the effective interest rates would have been approximately 17.6% and 26.5%, respectively, still materially higher than the stated coupon due to the substantial original issue discount.

Outstanding Principal

As of March 31, 2026, and December 31, 2025, the outstanding principal balance of the Convertible Debentures was $0 and $50,000, respectively.

Settlement and Extinguishment

On January 22, 2026, the Company delivered an irrevocable optional prepayment notice with respect to the Convertible Debentures.

On February 6, 2026, the Company settled the Convertible Debentures, which had an aggregate outstanding principal of $50,000 and a net carrying value of $38,021 (after unamortized debt discounts of $11,979 as of December 31, 2025), through a combination of (i) a cash payoff of approximately $38,903, consisting of $35,000 of principal, a $3,500 prepayment premium, and approximately $403 of accrued interest, and (ii) conversion of $15,000 of principal, with no accrued interest, at a conversion price of $4.00 per share, resulting in the issuance of 3,750,000 shares of the Company’s common stock.

The remaining unamortized debt discounts of $11,979 were fully amortized to interest expense upon settlement during the three months ended March 31, 2026, and are included in “Interest expense, net” in the unaudited condensed consolidated statements of operations.

In connection with the settlement, the Company recognized the following:

SCHEDULE OF SETTLEMENT


Loss on extinguishment of convertible debentures — prepayment premium	$	(3,500	)
Gain on derecognition of embedded derivative at settlement		443
Realized loss on extinguishment of convertible debentures	$	(3,057	)

Upon payment in full, the Convertible Debentures were satisfied and terminated, and all related security interests and liens were released.

We also entered into a SEPA with Yorkville that provided the Company with the right, but not the obligation, to sell shares of common stock during the commitment period. We terminated the SEPA effective January 29, 2026, and did not sell any shares under the SEPA.

Cross-references to related disclosures

Derivative-related qualitative, quantitative, and tabular disclosures are included in more than one note to the unaudited condensed consolidated financial statements. Accordingly, the Company provides the following cross-references:

	●	Note 4 — Business Acquisition (Exchangeable Shares issued as consideration and related acquisition disclosures)

	●	Note 12 — Fair Value Measurements (fair value hierarchy and valuation inputs for Level 3 instruments, as applicable)

	●	Note 13 — Stockholders’ Equity (Exchangeable Shares and Special Voting Preferred Stock; reclassification to equity)

	●	Note 14 — Options, Restricted Stock Units and Warrants (warrant terms and Fundamental Transaction cash settlement / repurchase activity)

- Definition

The entire disclosure for information about short-term and long-term debt arrangements, which includes amounts of borrowings under each line of credit, note payable, commercial paper issue, bonds indenture, debenture issue, own-share lending arrangements and any other contractual agreement to repay funds, and about the underlying arrangements, rationale for a classification as long-term, including repayment terms, interest rates, collateral provided, restrictions on use of assets and activities, whether or not in compliance with debt covenants, and other matters important to users of the financial statements, such as the effects of refinancing and noncompliance with debt covenants.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(16))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-8

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(b))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(4))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(3))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(22)(a))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(19))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-9

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(c))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481544/470-10-50-6

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 405
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477092/405-40-50-1

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 24: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 470
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/470/tableOfContent

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 835
-SubTopic 30
-Name Accounting Standards Codification
-Section 45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482925/835-30-45-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1B
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1B

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1C
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1C

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1E
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1E

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 1I
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481139/470-20-50-1I

+ Details

SCHEDULE OF CARRYING AMOUNT OF GOODWILL (Details) - USD ($)
$ in Thousands

3 Months Ended

May 28, 2025

Mar. 31, 2026

Intangible Asset, Goodwill and Other [Abstract]

Goodwill, beginning

^[1]

$ 70,984

Acquisition

$ 70,435

Impairment

Foreign currency translation adjustment

(1,226)

Goodwill, ending

$ 69,758

[1]

- Definition

Amount, after accumulated impairment loss, of asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References

+ Details

- Definition

Amount of impairment loss from asset representing future economic benefit arising from other asset acquired in business combination or from joint venture formation or both, that is not individually identified and separately recognized.

+ References + Details

SCHEDULE OF DERIVATIVE INSTRUMENTS ON EARNINGS (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2026 USD ($)
Fair Value Disclosures [Abstract]
Change in fair value of embedded derivative	$ 497

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE (Details) - USD ($)
$ in Thousands

Mar. 31, 2026

Dec. 31, 2025

Payables and Accruals [Abstract]

Accrued accounting and legal

$ 725

$ 705

Accrued consulting

564

406

Accrued interest

200

Accrued research and development expenses

167

169

Accrued office and other

Accrued insurance premium financing

^[1]

370

916

Accrued payroll

^[2]

1,180

512

Other accrued expenses

132

Accounts payable and accrued expenses

$ 3,179

$ 2,952

[1]

On August 27, 2025, the Company entered into a premium finance agreement for the policy period beginning August 3, 2025. The total premium was $2,172, of which $544 was paid as a down payment and $1,600 was financed. The agreement includes a finance charge of $51, resulting in total payments of $1,700 payable in nine monthly installments of $187 through May 2026 at an annual percentage rate of 7.48%. The financing obligation is secured by unearned premiums under the financed policies. As of March 31, 2026, the amount included in prepaid insurance is approximately $570 and AFCO loan payable of approximately $370. Prepaid insurance is amortized over the policy term, and the financing liability is reduced as payments are made. Interest expense is recognized using the effective interest method.

[2]

Includes approximately $779 related to severance and other separation-related obligations associated with the Company’s former Chief Financial Officer pursuant to a Separation and General Release Agreement entered into in March 2026. The accrued amount includes cash severance, pro rata bonus components, and other related obligations expected to be paid in accordance with the terms of the agreement.

SCHEDULE OF ASSETS MEASURED AT FAIR VALUE ON NONRECURRING BASIS (Details) - Fair Value, Inputs, Level 3 [Member] - Fair Value, Nonrecurring [Member] $ in Thousands	May 28, 2025 USD ($)
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Goodwill	$ 70,435
Trade Names [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of intangible assets	5,100
Developed Technology [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of intangible assets	40,000
Legal and Compliance Frame Work [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Fair value of intangible assets	$ 2,400

SCHEDULE OF VAIABLE INTEREST ENTITY ASSETS AND LIABILITIES (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Feb. 06, 2026	Dec. 31, 2025
Assets
Other assets held at cost – gold	$ 15,225
Cash	6,859	$ 38,903	20,316
Total assets	173,317		187,543
Liabilities
Accounts payable and accrued expenses	3,179		2,952
Total liabilities	13,971		$ 54,215
Streamex Ltd [Member]
Assets
Other assets held at cost – gold	15,225
Cash	60
Total assets	15,285
Liabilities
Accounts payable and accrued expenses	33
Total liabilities	$ 33

- Definition

Amount of asset recognized for present right to economic benefit.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S45
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477657/942-210-S45-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478478/942-210-S50-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(11))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-05(b)(1))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477314/942-235-S99-1

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 942
-SubTopic 235
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478671/942-235-S50-1

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 16: http://www.xbrl.org/2003/role/exampleRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 64
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481620/480-10-55-64

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 14
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-14

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 944
-SubTopic 605
-Name Accounting Standards Codification
-Section 55
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477548/944-605-55-11

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 49
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-49

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 27: http://www.xbrl.org/2003/role/exampleRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 10
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481372/852-10-55-10

Reference 28: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 29: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 35: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 36: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(12))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478777/944-210-S99-1

Reference 37: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(8))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 38: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(18))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 39: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 40: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 41: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

+ Details

- Definition

Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.

+ References

+ Details

- Definition

Amount of liability recognized for present obligation requiring transfer or otherwise providing economic benefit to others.

+ References

Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-6

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480738/235-10-S50-1

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 825
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 28
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482907/825-10-50-28

Reference 9: http://www.xbrl.org/2003/role/exampleRef
-Topic 480
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 64
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481620/480-10-55-64

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(B))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481231/810-10-45-25

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (bb)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-3

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 235
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(g)(1)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480678/235-10-S99-1

Reference 16: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(ii))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iii)(A))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(iv))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 946
-SubTopic 830
-Name Accounting Standards Codification
-Section 55
-Paragraph 12
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479168/946-830-55-12

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.6-04(14))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479170/946-210-S99-1

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1A
-Subparagraph (SX 210.13-01(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1A

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 470
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1B
-Subparagraph (SX 210.13-02(a)(4)(i))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480097/470-10-S99-1B

Reference 26: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 27: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 852
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481404/852-10-50-7

Reference 28: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 30
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-30

+ Details

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

3 Months Ended

Mar. 31, 2026

Payables and Accruals [Abstract]

ACCOUNTS PAYABLE AND ACCRUED EXPENSES

NOTE 10 – ACCOUNTS PAYABLE AND ACCRUED EXPENSES

Accounts payable and accrued expenses as of March 31, 2026, and December 31, 2025, consist of the following:

	March 31,		December 31,
	2026		2025
Accrued accounting and legal	$	725	$	705
Accrued consulting		564		406
Accrued interest		-		200
Accrued research and development expenses		167		169
Accrued office and other		41		38
Accrued insurance premium financing⁽¹⁾		370		916
Accrued payroll⁽²⁾		1,180		512
Other accrued expenses		132		6
	$	3,179	$	2,952

	(1)	On August 27, 2025, the Company entered into a premium finance agreement for the policy period beginning August 3, 2025. The total premium was $2,172, of which $544 was paid as a down payment and $1,600 was financed. The agreement includes a finance charge of $51, resulting in total payments of $1,700 payable in nine monthly installments of $187 through May 2026 at an annual percentage rate of 7.48%. The financing obligation is secured by unearned premiums under the financed policies. As of March 31, 2026, the amount included in prepaid insurance is approximately $570 and AFCO loan payable of approximately $370. Prepaid insurance is amortized over the policy term, and the financing liability is reduced as payments are made. Interest expense is recognized using the effective interest method.

	(2)	Includes approximately $779 related to severance and other separation-related obligations associated with the Company’s former Chief Financial Officer pursuant to a Separation and General Release Agreement entered into in March 2026. The accrued amount includes cash severance, pro rata bonus components, and other related obligations expected to be paid in accordance with the terms of the agreement.

Cover - $ / shares	3 Months Ended
Cover - $ / shares	Mar. 31, 2026	May 13, 2026
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Quarterly Report	true
Document Transition Report	false
Document Period End Date	Mar. 31, 2026
Document Fiscal Period Focus	Q1
Document Fiscal Year Focus	2026
Current Fiscal Year End Date	--12-31
Entity File Number	001-38659
Entity Registrant Name	STREAMEX CORP.
Entity Central Index Key	0001530766
Entity Tax Identification Number	26-4333375
Entity Incorporation, State or Country Code	DE
Entity Address, Address Line One	2431 Aloma Avenue
Entity Address, Address Line Two	Suite 243
Entity Address, City or Town	Winter Park
Entity Address, State or Province	FL
Entity Address, Postal Zip Code	32792
City Area Code	(203)
Local Phone Number	409-5444
Title of 12(b) Security	Common Stock, par value $0.001 per share
Trading Symbol	STEX
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		104,274,817
Entity Listing, Par Value Per Share	$ 0.001

PROPERTY AND EQUIPMENT (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
Property, Plant, and Equipment [Abstract]
Depreciation	$ 13	$ 18

STOCKHOLDERS’ EQUITY

3 Months Ended

Mar. 31, 2026

Equity [Abstract]

STOCKHOLDERS’ EQUITY

NOTE 13 – STOCKHOLDERS’ EQUITY

Preferred stock

The Company is authorized to issue 1,000,000 shares of $0.001 par value preferred stock. As of March 31, 2026 and December 31, 2025, the Company has designated 200 shares of Series A preferred stock, 600 shares of Series B preferred stock, 4,200 shares of Series C Preferred Stock, 1,400 shares of Series D Preferred Stock, 1,000 shares of Series E Preferred Stock, 200,000 shares of Series F Preferred Stock and 1 Special Voting Preferred Stock. As of March 31, 2026 and December 31, 2025, there were no issued or outstanding shares of Series A, Series B, Series D, Series E and Series F preferred stock.

Special Voting Preferred Stock

In connection with the issuance of Exchangeable Shares, the Company designated one share of Special Voting Preferred Stock, par value $0.001 per share. One share of Special Voting Preferred Stock was issued and outstanding as of March 31, 2026, and December 31, 2025.

The Special Voting Preferred Stock was issued to a trustee and does not have any economic rights, including rights to dividends or participation in liquidation, other than a nominal liquidation preference of $1.00. The Special Voting Preferred Stock is not convertible into common stock.

The sole purpose of the Special Voting Preferred Stock is to provide voting rights to holders of Exchangeable Shares on an equivalent basis with holders of the Company’s common stock. The holder of the Special Voting Preferred Stock is entitled to cast a number of votes equal to the aggregate number of votes that the holders of Exchangeable Shares would be entitled to cast if such Exchangeable Shares were exchanged for shares of the Company’s common stock, in accordance with the Exchange Rights Agreement.

The voting rights associated with the Special Voting Preferred Stock terminate automatically upon the exchange or cancellation of all outstanding Exchangeable Shares, at which time the Special Voting Preferred Stock is automatically cancelled for no consideration.

Series C Preferred Stock

Series C Preferred Stock (“Series C”) issued and outstanding totaled 105 shares as of March 31, 2026, and December 31, 2025. As of March 31, 2026, and December 31, 2025, the Company has accrued $123 and $121 dividends payable on the Series C, respectively. As of March 31, 2026, and December 31, 2025, the cumulative dividend per share payable on the Series C was approximately $1,175 and $1,153, respectively.

Each share of Series C is convertible at the holder’s option into shares of common stock at a conversion price of $0.3197 per share, based on the stated value of $1,000 per preferred share. As of March 31, 2026, the outstanding Series C shares were convertible into an aggregate of 434,845 shares of common stock, which includes 106,412 shares issuable for accrued dividends at a conversion rate of $1.1593 per share. The Series C is subject to full ratchet anti-dilution price protection upon issuance of equity or equity-linked securities at an effective price below $0.3197 per share, as well as customary anti-dilution adjustments for stock splits and similar events.

Common stock

The Company is authorized to issue 500,000,000 shares of $0.001 par value common stock. As of March 31, 2026, and December 31, 2025, the Company had 97,721,696 and 49,805,275 shares issued and outstanding, respectively.

Exchangeable Shares

During the three months ended March 31, 2026, holders of Exchangeable Shares converted a total of 24,571,166 Exchangeable Shares into an equal number of shares of the Company’s common stock. As of March 31, 2026 and December 31, 2025, the Company had 83,420,765 and 107,991,931 Exchangeable Shares outstanding, respectively, each of which is exchangeable on a one-for-one basis for a share of the Company’s common stock, subject to the terms of the exchange agreement.

Sale of Common Stock.

On January 22, 2026, the Company entered into an underwriting agreement with Needham & Company, LLC, as representative of the several underwriters, in connection with an underwritten public offering of the Company’s common stock. The Company issued 11,666,667 shares of common stock at a public offering price of $3.00 per share. The underwriters fully exercised their over-allotment option, resulting in the issuance of an additional 1,750,000 shares of common stock. Aggregate gross proceeds from the offering, including the over-allotment option, were approximately $40,250. The Company incurred transaction costs of approximately $3,066, including underwriting discounts, commissions, and other offering expenses, resulting in net proceeds of approximately $37,184.

ATM Sales Agreement 2024

As of March 31, 2026, the Company had approximately $4,500 of remaining capacity under its At The Market Offering Agreement with H.C. Wainwright & Co., LLC, dated December 18, 2024. No shares were sold under the ATM Offering during the three months ended March 31, 2026.

Equity Line of Credit

As of March 31, 2026, the Company had approximately $5,000 of remaining capacity under its Equity Subscription Agreement with Lind Global Fund III, LP, dated February 28, 2025, subject to the filing and effectiveness of a registration statement. No advances have been made under the Subscription Agreement as of March 31, 2026.

- Definition

The entire disclosure for equity.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-1

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-1

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-1

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 1
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480070/505-10-S50-1

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-3

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-3

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S45
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480100/505-10-S45-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-2

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 4
-Subparagraph (SAB Topic 4.C)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480008/505-10-S99-4

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 30
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481520/505-30-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.D.2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479921/505-20-S99-1

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S50
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479951/505-20-S50-3

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 855
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 1.B.3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480148/855-10-S99-1

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 20
-Name Accounting Standards Codification
-Section S25
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479982/505-20-S25-3

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/505/tableOfContent

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S50
-Paragraph 11
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480657/210-10-S50-11

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 5
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-5

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480434/815-10-50-8A

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 235
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477968/946-235-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 946
-SubTopic 505
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478448/946-505-50-6

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 815
-SubTopic 40
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480237/815-40-50-6

Reference 31: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 32: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 13
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-13

Reference 33: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 34: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 14
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-14

Reference 35: http://www.xbrl.org/2003/role/disclosureRef
-Topic 505
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 16
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481112/505-10-50-16

+ Details

COMMITMENTS AND CONTINGENCIES (Details Narrative) $ in Thousands	3 Months Ended
	Mar. 31, 2026 USD ($)
Commitments and Contingencies Disclosure [Abstract]
Consulting fees	$ 4,000
base fees	4,000
Other prepaid expense	$ 2,785

GOLD ASSETS (Details Narrative) - USD ($) $ in Thousands		3 Months Ended	12 Months Ended
GOLD ASSETS (Details Narrative) - USD ($) $ in Thousands	Feb. 05, 2026	Mar. 31, 2026	Dec. 31, 2025	Feb. 28, 2026	Nov. 04, 2025
Aggregate carrying value			$ 24,472
Inventory write-down			0
Cash proceeds	$ 26,410
Recognized gain sale of gold	2,938	$ 0
Purchase of gold assets		14,225
Other assets held at cost - gold		15,225
Maximum [Member] \| Brinks Bailee Agreement [Member]
Other liabilities					$ 125,000
Restricted [Member]
Aggregate carrying value			23,472
Unrestricted [Member]
Aggregate carrying value		1,000	1,000	$ 1,000
Restricted Gold [Member]
Held for sale with carrying amount	$ 23,472		$ 23,472

SEGMENT REPORTING

3 Months Ended

Mar. 31, 2026

Segment Reporting [Abstract]

SEGMENT REPORTING

NOTE 17 – SEGMENT REPORTING

Chief Operating Decision Maker (CODM) and Segment Evaluation

On May 28, 2025, in connection with the acquisition of Streamex Exchange, the Company appointed Henry McPhie, former co-founder and CEO of Streamex Exchange, as its new Chief Executive Officer and a member of the Board of Directors. As a result of this leadership change, Mr. McPhie was designated as the Company’s new Chief Operating Decision Maker (“CODM”), replacing Anthony Amato, the Company’s former CEO and director.

Following this change, the Company re-evaluated its operating and reportable segments based on the internal financial information reviewed by the CODM for purposes of performance assessment and resource allocation. Although the acquisition of Streamex Exchange introduced a new line of business focused on digital asset infrastructure, the CODM has not yet begun reviewing Streamex Exchange’s operating results separately for purposes of performance assessment or resource allocation. As of March 31, 2026, the CODM continues to evaluate the Company’s financial performance on a consolidated basis, and the internal reporting structure has not been modified to reflect discrete segment-level financial information.

Management believes that a transitional period is appropriate given the timing of the acquisition, the pre-revenue status of Streamex Exchange, and the pending financing and shareholder approvals necessary to operationalize the Streamex Exchange platform. Accordingly, the Company has concluded that no change in reportable segments has occurred as of March 31, 2026. The Company will continue to monitor the CODM’s review practices and internal reporting structure and will update its segment disclosures in future periods if and when discrete financial information is regularly reviewed at the segment level.

In accordance with ASC 280-10-50-34, if a change in reportable segments occurs in a future period, the Company will recast prior-period segment disclosures retrospectively to reflect the new segment structure.

Basis of Segmentation

The Company’s CODM evaluates financial performance and allocates resources on a consolidated basis. The Company manages its operations as one integrated business, and the CODM does not receive or review separate financial information for Streamex Exchange or any other business unit. This approach reflects the manner in which the CODM:

	●	Assesses performance against budgeted targets;
	●	Forecasts future financial results;
	●	Makes strategic and operational decisions;
	●	Allocates resources across the organization.

Accordingly, the Company has determined that it operates as one reportable and operating segment as of March 31, 2026.

Management continues to evaluate whether the Streamex Exchange business may become a separate reportable segment in future periods, depending on the scale and financial significance, and the CODM’s review of discrete operating results.

Segment Performance Measures

The primary measure used by the CODM to assess performance is consolidated net loss, which is reviewed in conjunction with other consolidated financial metrics. The CODM also evaluates actual results against budgeted amounts and considers consolidated operating results in making decisions about research and development investments and other strategic initiatives.

Segment assets are not separately reported to or reviewed by the CODM. Therefore, the Company does not disclose segment asset information. All assets are managed on a consolidated basis and are reported in the Company’s unaudited condensed consolidated balance sheets.

The Company does not currently disclose geographic revenue or customer concentration by segment, as such information is not reviewed by the CODM. However, this will be reassessed as operations evolve.

Revenue and Expense Information

Information concerning the operations of the Company’s reportable segments is as follows:

SCHEDULE OF SEGMENT REPORTING

	2026			2025
	For the Three Months Ended March 31,
	2026			2025

Revenues	$	-		$	-
Less Segment expenses:
Research and development		-			6
General and administrative		8,884			883
General and administrative - stock-based compensation expenses		25,370			2,074
Depreciation and amortization		1,492			21
Total operating and segment expense		(35,746	)		(2,984	)
Plus:
Interest expense, net		(12,195	)		-
Realized gain on sale of gold		2,938			-
Realized gain on marketable securities		484			-
Change in fair value of marketable securities		(134	)		-
Change in fair value of embedded derivative		497			-
Realized loss on extinguishment of convertible debenture		(3,057	)		-
Realized loss on investment		(119	)		-
Gain on settlement and forgiveness of debt		-			199
Other income (expense), net		73			(15	)
Total other income (expense)		(11,513	)		184
Income taxes (benefit)		(565	)		-
Segment Net Loss	$	(46,694	)	$	(2,800	)
Non-controlling interest		1			(12	)
Net loss attributable to Streamex Corp.	$	(46,693	)	$	(2,812	)

- Definition

The entire disclosure for segment reporting.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 40
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-40

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 42
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-42

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 34
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-34

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (ee)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 31
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-31

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26C
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26C

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26B
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26B

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 22
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-22

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 15
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-15

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 41
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-41

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 21
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-21

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 32
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-32

Reference 15: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 48
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-48

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 270
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482964/270-10-50-1

Reference 17: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 18: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 19: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 20: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 21: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 54
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-54

Reference 22: http://www.xbrl.org/2003/role/exampleRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 47
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482785/280-10-55-47

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/280/tableOfContent

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 280
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 26
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482810/280-10-50-26

+ Details

SCHEDULE OF TANGIBLE AND IDENTIFIABLE INTANGIBLE ASSETS ACQUIRED AND LIABILITIES ASSUMED (Details) $ in Thousands	May 28, 2025 USD ($)
Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]
Cash	$ 366
Due from related party	11
Sales tax receivable	14
Prepaid expenses	22
Trade name	5,100
Developed technology	40,000
Legal and compliance framework	2,400
Goodwill	70,435
Total assets acquired	118,348
Accounts payable and accrued expenses	(262)
Deferred tax liability	(12,588)
Total liabilities assumed	(12,850)
Net assets acquired	$ 105,498

SCHEDULE OF INTANGIBLE ASSETS (Details) - USD ($)
$ in Thousands

Mar. 31, 2026

Dec. 31, 2025

May 28, 2025

Intangible Asset, Finite-Lived [Line Items]

Total

$ 47,880

Foreign currency translation adjustment

(456)

371

Total accumulated amortization

(5,006)

(3,612)

Intangible assets, net

42,418

44,639

Trade Names [Member]

Intangible Asset, Finite-Lived [Line Items]

Total accumulated amortization

(425)

(303)

Developed Technology Rights [Member]

Intangible Asset, Finite-Lived [Line Items]

Total accumulated amortization

(4,162)

(2,975)

Legal Contact [Member]

Intangible Asset, Finite-Lived [Line Items]

Total accumulated amortization

(285)

(204)

Patents [Member]

Intangible Asset, Finite-Lived [Line Items]

Total accumulated amortization

(134)

(130)

Trade Names [Member]

Intangible Asset, Finite-Lived [Line Items]

Total

5,100

^[1]

5,100

^[1]

$ 5,100

Developed Technology Rights [Member]

Intangible Asset, Finite-Lived [Line Items]

Total

^[1]

40,000

Legal and Compliance Frame Work [Member]

Intangible Asset, Finite-Lived [Line Items]

Total

2,400

^[1]

2,400

^[1]

$ 2,400

Patents [Member]

Intangible Asset, Finite-Lived [Line Items]

Total

$ 380

[1]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS

3 Months Ended

Mar. 31, 2026

Equity [Abstract]

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS

NOTE 14 – OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS

Streamex Corp.

2023 Long-Term Incentive Plan

Stockholders approved the Third Amendment to the Company’s 2023 Long-Term Incentive Plan (the “Incentive Plan Amendment”) on September 5, 2025, increasing the total number of shares authorized for issuance under the plan by 10,359,211 shares, from 4,376,595 shares to 14,735,806 shares.

Stockholders approved the Fourth Amendment to the Company’s 2023 Long-Term Incentive Plan on December 30, 2025, increasing the total number of shares authorized for issuance under the plan by 22,494,324 shares, from 14,735,806 shares to 37,230,130 shares.

As of March 31, 2026, there were 18,109,340 shares available under the 2023 Long-Term Incentive Plan.

Options

Option valuation models require the input of highly subjective assumptions. The fair value of stock-based payment awards was estimated using the Black-Scholes option model with a volatility figure derived from historical stock prices of the Company. The Company accounts for the expected life of options based on the contractual life of options for non-employees.

For employees, the Company accounts for the expected life of options in accordance with the “simplified” method, which is used for “plain-vanilla” options, as defined in the accounting standards codification. The risk-free interest rate was determined from the implied yields of U.S. Treasury zero-coupon bonds with a remaining life consistent with the expected term of the options.

The following table presents information related to stock options as of March 31, 2026:

Options Outstanding						Options Exercisable
Exercise		Number of		Weighted Average Remaining Life		Exercisable Number of
Price		Options		In Years		Options
$	Under 9.99		2,900,000		8.6		2,900,000
$	10.00-19.99		15,000		7.1		15,000
$	20.00-49.99		3,000		3.0		3,000
$	50.00-69.99		3,000		3.8		3,000
			2,921,000		8.6		2,921,000

A summary of the stock option activity and related information for the Plan for the three months ended March 31, 2026 is as follows:

SCHEDULE OF STOCK OPTION ACTIVITY

	Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at January 1, 2026		2,736,000		$	0.78		8.7	$	6,744,540
Issued		250,000		$	3.21		9.8
Forfeited/expired		(65,000	)	$	5.01
Outstanding at March 31, 2026		2,921,000		$	0.89		8.6	$	1,709,540
Exercisable at March 31, 2026		2,921,000		$	0.89		8.6	$	1,709,540

The aggregate intrinsic value in the preceding table represents the total pretax intrinsic value, based on options with an exercise price less than the stock price of the Company of $1.13 as of March 31, 2026, which would have been received by the option holders had those option holders exercised their options as of that date.

During the three months ended March 31, 2026, the Company granted an aggregate of 250,000 options to purchase the Company’s common stock at a weighted average exercise price of $3.21 per share for a term of ten years. The options vested immediately upon grant and the full grant-date fair value of approximately $770 was recognized as stock-based compensation expense during the three months ended March 31, 2026.

Stock based compensation expense related to stock options recognized during the three months ended March 31, 2026 and 2025, was $770 and $40, respectively, which is presented within general and administrative expenses in the unaudited Condensed Consolidated Statements of Operations. As of March 31, 2026, there was no unrecognized compensation expense related to stock options.

On May 23, 2025, in connection with the Company’s acquisition of Streamex Exchange, the Company entered into an amendment to the Executive Employment Agreement with the Company’s former Chief Executive Officer and Chairman of the Board. Pursuant to the amendment, all previously granted equity awards to the former Chief Executive Officer and Chairman of the Board including vested and unvested stock options were accelerated and deemed fully vested and nonforfeitable as of May 28, 2025. In addition, the post-resignation exercise period for all vested options was extended to the later of the original expiration date or 36 months following the transaction closing.

Assumption	Value
Weighted average grant date fair value	$	3.08
Expected volatility		124.17	%
Risk-free interest rate		4.15	%
Expected dividend yield		0.00	%
Expected Term (in years)		5.0

Warrants

The following table summarizes information with respect to outstanding warrants to purchase common stock of Streamex Corp. as of March 31, 2026:

Exercise Price		Number of Warrants		Expiration Date
$	0.3000		11,982	Nov-28
	0.9547		577,916	Sep-28
	3.3640		117,828	Jul-29
	4.0660		25,000	Nov-32
	4.4550		107,483	Jun-28
	4.4660		5,580	Apr-29
	4.6626		49,550	Mar-29
	4.9252		71,593	Mar-29
	4.9290		99,243	Jul-28
	5.1358		83,270	Jul-28
	7.1810		9,846	Jul-28
	7.5020		21,369	Aug-28
	7.9630		21,709	Jun-27
	9.0000		84,390	Jan-29
	9.5960		19,118	Aug-28
	10.0992		51,705	Sep-28
	10.2600		84,296	Sep-28
	10.4678		40,417	Oct-28
	11.3000		96,198	Nov-28
	13.2800		12,500	Jul-26
	48.0000		56,892	Nov-27
	61.6000		11,982	Nov-28
			1,647,885

During the three months ended March 31, 2026, the Company issued 54,647 shares of its common stock upon cashless exercise of 87,984 warrants to purchase shares of common stock, pursuant to the formula set forth in such warrants.

A summary of the warrant activity for three months ended March 31, 2026 is as follows:

SCHEDULE OF WARRANT ACTIVITY

	Shares			Weighted-Average Exercise Price		Weighted-Average Remaining Contractual Term		Aggregate Intrinsic Value
Outstanding at January 1, 2026		1,735,869		$	6.94		2.8	$	1,414,626
Issued		-			-		-
Forfeited/expired		-			-		-		-
Exercised		(87,984	)		0.95		-		-
Outstanding at March 31, 2026		1,647,885		$	7.26		2.6	$	111,231

Vested and expected to vest at March 31, 2026		1,647,885		$	7.26		2.6	$	111,231
Exercisable at March 31, 2026		1,647,885		$	7.26		2.6	$	111,231

The aggregate intrinsic value in the preceding tables represents the total pretax intrinsic value, based on warrants with an exercise price less than the company’s stock price of $1.13 as of March 31, 2026, which would have been received by the warrant holders had those warrant holders exercised their warrants as of that date.

Restricted Stock Units

The following table summarizes the restricted stock activity for the three months ended March 31, 2026:

SCHEDULE OF RESTRICTED STOCK ACTIVITY

	Number of Shares			Weighted-Average Grant Date Fair Value Per Share
Restricted shares issued as of January 1, 2026		2,037,500		$	5.36
Granted		8,868,316		$	2.91
Vested and issued		(6,123,941	)	$	3.01
Forfeited		(198,500	)	$	3.21
Total		4,583,375		$	3.86
Comprised of:
Vested restricted shares as of March 31, 2026		301,500		$	3.21
Unvested restricted shares as of March 31, 2026		4,281,875		$	3.90

Stock based compensation expense related to RSU grants was $24,545 and $2,236 for the three months ended March 31, 2026 and 2025, respectively, which is included in general and administrative expenses in the unaudited condensed consolidated statements of operations. As of March 31, 2026, total unrecognized stock-based compensation cost related to unvested RSUs was approximately $24,545, which is expected to be recognized over a weighted-average period of approximately 1.33 years.

The following table summarizes the terms of individual RSU grants issued during the three months ended March 31, 2026 that were subject to vesting conditions extending beyond the grant date:

Grant Date	Recipient	RSUs Granted		Vesting Terms	GDFV¹
1/1/2026	Third-party consultant		250,000	25,000 immediately; remainder quarterly	$	758
1/8/2026	Interim Executive Chairman		100,000	4 equal quarterly installments over 1 year	$	321
1/8/2026	Chief Executive Officer		1,000,000	100,000 on May 15, 2026; 900,000 in 16 quarterly installments over 4 years	$	3,210
1/27/2026	Third-party consultant		125,000	16 quarterly installments over 4 years	$	456
2/1/2026	Third-party consultant		500,000	300,000 immediately; 200,000 in 4 quarterly installments over 12 months	$	1,790
3/3/2026	Third-party consultant		425,000	212,500 immediately; 125,000 on Jun 3; 87,500 on Sep 3, 2026	$	876
3/16/2026	Third-party consultant		65,000	5,000 immediately; remainder monthly	$	119
3/16/2026	Chief Financial Officer		500,000	16 quarterly installments over 4 years	$	915
			2,965,000		$	8,445

(1)

Grant-date fair value (“GDFV”)

Performance-Based Restricted Stock Units

During the three months ended March 31, 2026, the Company granted performance-vesting restricted stock units (“PSUs”) to certain consultants. The PSUs represent the right to receive shares of the Company’s common stock upon the achievement of specified performance conditions or market conditions, and satisfaction of service requirements, subject to certification by the Company’s Board of Directors or its Compensation Committee (the “Committee”). The PSUs are equity-classified awards and settle solely in shares of the Company’s common stock. No cash settlement alternative exists.

Stock Price-Based PSUs

On February 1, 2026, the Company granted 500,000 PSUs to a third-party consultant, under a consulting agreement effective February 1, 2026. The PSUs vest in five tranches upon the achievement of specified stock price milestones, measured by the closing price of the Company’s common stock on a U.S. national securities exchange, as follows: 100,000 shares at $5.00; 100,000 shares at $6.00; 100,000 shares at $8.00; 100,000 shares at $10.00; and 100,000 shares at $12.00. Each milestone is certified by the Committee in good faith, and the consultant must be providing continuous service through the certification date. All unvested PSUs are forfeited immediately upon cessation of service. The stock price milestones and shares issuable per tranche are subject to equitable adjustment for stock splits, reverse stock splits, and similar events under the Company’s 2023 Long-Term Incentive Plan.

The stock price targets represent market conditions because they relate to the achievement of specified stock prices of the Company’s equity instruments. In accordance with ASC 718, the effect of the market conditions is reflected in the estimate of the grant-date fair value of the awards. The Company estimated the grant-date fair value of each tranche using a Monte Carlo simulation model, which incorporated the following significant assumptions:

Assumption	Value
Grant-date stock price		$3.58
Stock price milestones		$5.00 – $12.00
Expected volatility		152.9%
Risk-free interest rate		3.72%
Expected dividend yield		0.00%
Derived service periods (range)		3.43 – 7.41 years

The following table summarizes the grant-date fair value by tranche (in thousands, except per unit data and units):

Tranche	Milestone		GDFV¹/Unit		Units		Agg FV²		DSP³ (yrs)		Q1 2026 Expense
1	$	5.00	$	3.56		100,000	$	356		3.43	$	17
2	$	6.00	$	3.55		100,000	$	355		4.58	$	12
3	$	8.00	$	3.57		100,000	$	357		5.99	$	9
4	$	10.00	$	3.56		100,000	$	356		6.84	$	8
5	$	12.00	$	3.54		100,000	$	354		7.41	$	8
						500,000	$	1,778			$	54

	(1)	GDFV per unit, determined using a Monte Carlo simulation model. The weighted-average grant-date fair value per unit for the stock price-based PSUs was $3.56.
	(2)	Aggregate fair value (“Agg FV”)
	(3)	Derived service period (“DSP”)

The aggregate grant-date fair value of the 500,000 stock price-based PSUs was approximately $1,778. In accordance with ASC 718-10-25-8, compensation cost is recognized on a straight-line basis over the derived service period for each tranche, regardless of whether the stock price milestones are ultimately achieved. Previously recognized compensation cost is not reversed if a market condition is not satisfied, provided that all necessary service has been rendered.

During the three months ended March 31, 2026, the Company recognized stock-based compensation expense of approximately $54 related to the stock price-based PSUs, which is included in general and administrative expenses in the unaudited condensed consolidated statements of operations. As of March 31, 2026, unrecognized compensation cost related to the stock price-based PSUs was approximately $1,724, however, following the consultant’s resignation in April 2026, the remaining unrecognized compensation cost associated with the unvested stock price-based PSUs will not be recognized in future periods because the requisite service condition will no longer be satisfied.

The consultant is also entitled to 500,000 time-based RSUs (300,000 vesting on the effective date and 200,000 vesting quarterly over 12 months), which are separately disclosed in the RSU section above.

AUM-Based PSUs

On March 16, 2026, the Company granted up to 1,000,000 PSUs to a third-party consultant, vesting upon the achievement of assets under management (“AUM”) milestones related to the Company’s rare earth elements (“REE”) Fund (a planned commodity-linked investment product): (i) 50,000 units upon launch of the REE Fund (subject to a dollar cap of $150); (ii) 100,000 units when AUM exceeds $500 million (subject to a dollar cap of $350); and (iii) 850,000 units when AUM exceeds $1 billion (subject to a dollar cap of $3,000). The number of shares issuable under each tranche is the lesser of the fixed share amount or the dollar cap divided by the fair value per share at each vesting date. Although the number of shares is variable, the dollar caps function as a ceiling on value deliverable to the consultant and do not require delivery of a fixed monetary amount; the consultant bears downside stock price risk. The Company evaluated the award under ASC 480 and ASC 815 and concluded it does not meet the criteria for liability classification or derivative accounting. The award is equity-classified and indexed to the Company’s own stock.

These PSUs contain performance conditions under ASC 718. The grant-date fair value per unit was determined based on the closing price of the Company’s common stock of $1.83 on the grant date of March 16, 2026. At the grant-date stock price of $1.83, none of the dollar caps were binding (the lowest implied cap price is $3.00 for Tranche 1), and accordingly the grant-date fair value per unit equals $1.83 for all tranches. The aggregate grant-date fair value of the AUM-based PSUs is approximately $1,830 (based on the grant-date stock price of $1.83 applied to 1,000,000 units at the maximum fixed share amounts), subject to a maximum aggregate dollar cap of $3,500 (consisting of $150 for the first tranche, $350 for the second tranche, and $3,000 for the third tranche). The dollar caps limit the maximum value deliverable to the consultant regardless of the stock price at vesting. As of March 31, 2026, management assessed the probability of achieving each AUM-based performance condition on a tranche-by-tranche basis and concluded that no condition is probable. The launch of a REE Fund would require, among other things, formation of a legal entity, preparation of offering documents, establishment of custody and pricing infrastructure for rare earth elements, and satisfaction of applicable regulatory requirements — none of which had been initiated as of the reporting date. The AUM-based milestones ($500 million and $1 billion) are sequentially dependent on fund launch and were assessed as remote. Accordingly, no stock-based compensation expense was recognized during the three months ended March 31, 2026. The Company recognizes compensation cost only when achievement of the applicable performance condition is considered probable, on a straight-line basis over the requisite service period.

Summary of PSU Awards

As of March 31, 2026, total stock-based compensation expense recognized for PSU awards during the three months ended March 31, 2026 was approximately $54, consisting entirely of expense related to the stock price-based PSUs. For the AUM-based PSUs, management assessed the probability of achieving each performance condition on a tranche-by-tranche basis and concluded that no condition met the “probable” threshold under ASC 718; accordingly, no expense was recognized.

Total unrecognized compensation cost related to outstanding PSUs was approximately $1,724 as of March 31, 2026, consisting of $1,724 related to stock price-based PSUs (to be recognized over a weighted-average period of approximately 5.5 years) and $0 related to AUM-based PSUs (to be recognized when achievement becomes probable, with an aggregate grant-date fair value of approximately $1,830, subject to a maximum dollar cap of $3,500).

The Company accounts for forfeitures as they occur. No forfeitures of PSUs were recognized during the three months ended March 31, 2026.

The following table summarizes PSU activity for the three months ended March 31, 2026:

	PSUs – Stock Price		PSUs - AUM		Total PSUs
Nonvested as of December 31, 2025		-		-		-
Granted		500,000		1,000,000		1,500,000
Vested and issued		-		-		-
Forfeited		-		-		-
Nonvested as of March 31, 2026		500,000		1,000,000		1,500,000

The table above excludes (i) performance-based restricted stock units tied to Organic Gross Revenue Growth targets, under which certain consultants may earn additional units annually based on achievement of annual revenue growth targets established and certified by the Compensation Committee, as the number of units issuable is not determinable until the applicable targets are set, and (ii) PSU grants to four third-party consultants, involving an aggregate of up to approximately 910,000 units tied to cumulative gross revenue and token-related performance milestones, that have not been approved by the Board of Directors or the Compensation Committee as of March 31, 2026 and are therefore not considered granted under ASC 718.

ViralClear Pharmaceuticals, Inc.

2019 Long-Term Incentive Plan

There are 2,915,071 shares remaining available for future issuance of awards under the terms of the ViralClear Plan.

Warrants (ViralClear)

A summary of the warrant activity for three months ended March 31, 2026 is as follows:

SUMMARY OF WARRANT ACTIVITY

					Weighted-Average
					Remaining
			Weighted-Average		Contractual
	Shares		Exercise Price		Term
Outstanding at January 1, 2026		473,772	$	5.00		1.9
Forfeited/expired		-		-		-
Outstanding at March 31, 2026		473,772	$	5.00		1.6
Exercisable at March 31, 2026		473,772	$	5.00		1.6

The following table presents information related to warrants (ViralClear) at March 31, 2026:

SCHEDULE OF RELATED TO WARRANTS

Exercise		Number		Expiration
Price		Outstanding		Date
$	5.00		473,772		November 2027

Restricted stock units (ViralClear)

The following table summarizes the restricted stock activity for the three months ended March 31, 2026:

Restricted shares outstanding at January 1, 2026:			678,679
Forfeited			-
Total restricted shares outstanding at March 31, 2026:			678,679

Comprised of:
Vested restricted shares as of March 31, 2026			678,679
Unvested restricted shares as of March 31, 2026			-
Total			678,679

BioSig AI Sciences, Inc.

Warrants (BioSig AI)

The following table summarizes information with respect to outstanding warrants to purchase common stock of BioSig AI at March 31, 2026:

SCHEDULE OF OUTSTANDING TO WARRANTS

Exercise		Number		Expiration
Price		Outstanding		Date
$	1.00		130,500		June-July 2028

STREAMEX LTD. (VIE) (Tables)

3 Months Ended

Mar. 31, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

SCHEDULE OF VAIABLE INTEREST ENTITY ASSETS AND LIABILITIES

Streamex Ltd. assets and liabilities included in the unaudited condensed consolidated balance sheet as of March 31, 2026:


Assets
Other assets held at cost – gold	$	15,225
Cash		60
Total assets	$	15,285

Liabilities
Accounts payable and accrued expenses	$	33
Total liabilities	$	33

- Definition

Tabular disclosure of the significant judgments and assumptions made in determining whether a variable interest (as defined) held by the entity requires the variable interest entity (VIE) (as defined) to be consolidated and (or) disclose information about its involvement with the VIE, individually or in aggregate (as applicable); the nature of restrictions, if any, on the consolidated VIE's assets and on the settlement of its liabilities reported by an entity in its statement of financial position, including the carrying amounts of such assets and liabilities; the nature of, and changes in, the risks associated with involvement in the VIE; how involvement with the VIE affects the entity's financial position, financial performance, and cash flows; the lack of recourse if creditors (or beneficial interest holders) of the consolidated VIE have no recourse to the general credit of the primary beneficiary (if applicable); the terms of arrangements, giving consideration to both explicit arrangements and implicit variable interests, if any, that could require the entity to provide financial support to the VIE, including events or circumstances that could expose the entity to a loss; the methodology used by the entity for determining whether or not it is the primary beneficiary of the variable interest entity; the significant factors considered and judgments made in determining that the power to direct the activities of a VIE that most significantly impact the VIE's economic performance are shared (as defined); the carrying amounts and classification of assets and liabilities of the VIE included in the statement of financial position; the entity's maximum exposure to loss, if any, as a result of its involvement with the VIE, including how the maximum exposure is determined and significant sources of the entity's exposure to the VIE; a comparison of the carrying amounts of the assets and liabilities and the entity's maximum exposure to loss; information about any liquidity arrangements, guarantees, and (or) other commitments by third parties that may affect the fair value or risk of the entity's variable interest in the VIE; whether or not the entity has provided financial support or other support (explicitly or implicitly) to the VIE that it was not previously contractually required to provide or whether the entity intends to provide that support, including the type and amount of the support and the primary reasons for providing the support; and supplemental information the entity determines necessary to provide.

+ References + Details

PROPERTY AND EQUIPMENT

3 Months Ended

Mar. 31, 2026

Property, Plant, and Equipment [Abstract]

PROPERTY AND EQUIPMENT

NOTE 6 – PROPERTY AND EQUIPMENT

Property and equipment as of March 31, 2026, and December 31, 2025 is summarized as follows:

SCHEDULE OF PROPERTY AND EQUIPMENT

	March 31,			December 31,
	2026			2025
Computer equipment	$	531		$	531
Furniture and fixtures		109			109
Testing/Demo equipment		312			312
Leasehold improvements		84			84
Total		1,036			1,036
Less accumulated depreciation		(1,024	)		(1,011	)
Property and equipment, net	$	12		$	25

As of March 31, 2026, the Company evaluated whether any events or changes in circumstances indicated that the carrying amounts of its property and equipment may not be recoverable. Based on this assessment, no impairment indicators were identified and no impairment charges were recorded during the three months ended March 31, 2026 or 2025.

Depreciation expenses were $13 and $18 for the three months ended March 31, 2026 and 2025, respectively.

- Definition

The entire disclosure for property, plant, and equipment. Includes, but is not limited to, land and land improvement; building; machinery and equipment; furniture and fixture; and work of art, historical treasure, or similar asset classified as collection.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (b)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-3

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-Name Accounting Standards Codification
-Publisher FASB
-URI https://asc.fasb.org/360/tableOfContent

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482099/360-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 13
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482130/360-10-45-13

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 360
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 5.CC)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480091/360-10-S99-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-SubTopic 360
-Topic 958
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477798/958-360-50-6

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-SubTopic 360
-Topic 958
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477798/958-360-50-1

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-SubTopic 360
-Topic 958
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477798/958-360-50-7

+ Details

SCHEDULE OF STOCK OPTION ACTIVITY (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2026	Dec. 31, 2025
Equity [Abstract]
Outstanding shares	2,736,000
Weighted Average Exercise Price Outstanding	$ 0.78
Weighted-Average Remaining Contractual Term	8 years 7 months 6 days	8 years 8 months 12 days
Outstanding Aggregate Intrinsic Value	$ 6,744,540
Grants	250,000
Weighted Average Exercise Price Grants	$ 3.21
Weighted-Average Remaining Contractual Term	9 years 9 months 18 days
Forfeited/expired	(65,000)
Weighted Average Exercise Price Forfeited/expired	$ 5.01
Outstanding shares	2,921,000	2,736,000
Weighted Average Exercise Price Outstanding	$ 0.89	$ 0.78
Outstanding Aggregate Intrinsic Value	$ 1,709,540	$ 6,744,540
Outstanding shares Exercisable	2,921,000
Weighted Average Exercise Price Outstanding	$ 0.89
Weighted-Average Remaining Contractual Term	8 years 7 months 6 days
Outstanding Exercisable Aggregate Intrinsic Value	$ 1,709,540

SCHEDULE OF SEGMENT REPORTING (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2026

Mar. 31, 2025

Segment Reporting [Line Items]

Revenues

Research and development

General and administrative

34,254

2,957

Depreciation and amortization

1,492

Total operating and segment expense

(35,746)

(2,984)

Interest expense, net

(12,195)

Realized gain on marketable securities

484

Realized loss on investment

(119)

Gain on settlement and forgiveness of debt

(3,057)

Other income (expense), net

(15)

Total other income (expense), net

(11,513)

184

Income taxes (benefit)

565

Net loss

(46,694)

(2,800)

Non-controlling interest

^[1]

(12)

Net loss attributable to Streamex Corp.

(46,693)

(2,812)

Corporate Segment [Member]

Segment Reporting [Line Items]

Revenues

Research and development

General and administrative

8,884

883

General and administrative - stock-based compensation expenses

25,370

2,074

Depreciation and amortization

1,492

Total operating and segment expense

(35,746)

(2,984)

Interest expense, net

(12,195)

Realized gain on sale of gold

2,938

Realized gain on marketable securities

484

Change in fair value of marketable securities

(134)

Change in fair value of embedded derivative

497

Realized loss on extinguishment of convertible debenture

(3,057)

Realized loss on investment

(119)

Gain on settlement and forgiveness of debt

199

Other income (expense), net

(15)

Total other income (expense), net

(11,513)

184

Income taxes (benefit)

(565)

Net loss

(46,694)

(2,800)

Non-controlling interest

(12)

Net loss attributable to Streamex Corp.

$ (46,693)

$ (2,812)

[1]	Less than $0.5 thousand

SUBSEQUENT EVENTS (Details Narrative) - shares						1 Months Ended		3 Months Ended
SUBSEQUENT EVENTS (Details Narrative) - shares	May 01, 2026	Apr. 17, 2026	Apr. 10, 2026	Apr. 06, 2026	Feb. 06, 2026	May 31, 2026	May 14, 2026	Mar. 31, 2026	Mar. 31, 2025
Subsequent Event [Line Items]
Number of shares issued					3,750,000
Shares vested
Common Stock [Member]
Subsequent Event [Line Items]
Number of shares issued									4,403,166
Subsequent Event [Member] \| Employment Agreement [Member] \| Common Stock [Member]
Subsequent Event [Line Items]
Shares vested							1,157,973
Shares converted							5,890,148
Subsequent Event [Member] \| Employment Agreement [Member] \| Common Stock [Member] \| Related Party [Member]
Subsequent Event [Line Items]
Shares vested							723,611
Subsequent Event [Member] \| Board of Directors Chairman [Member]
Subsequent Event [Line Items]
Dividend payment description		On April 17, 2026, the Board of Directors of Streamex Ltd., acting through GLDY ServiceCo, LLC as servicer, declared a scrip dividend of 0.000085 ounces of gold per GLDY Token for the month of March 2026, payable on April 17, 2026 to tokenholders of record as of that date. The dividend was funded by gold lease income earned on Streamex Ltd.’s gold holdings during March 2026 and was paid in the form of additional fractional GLDY Tokens. Each GLDY Token continues to represent one troy ounce of gold on a 1:1 basis, as confirmed by the third-party fund administrator. The noncontrolling interest holders’ share of the dividend was not material.
Subsequent Event [Member] \| Chief Investment Officer [Member] \| Employment Agreement [Member]
Subsequent Event [Line Items]
Number of shares issued	300,000
Subsequent Event [Member] \| Chief Investment Officer [Member] \| Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Number of shares granted				1,250,000
Shares issued				1,000,000
Subsequent Event [Member] \| Chief Investment Officer [Member] \| Performance Vesting Restricted Stock Units [Member] \| Employment Agreement [Member]
Subsequent Event [Line Items]
Number of shares granted	1,500,000
Subsequent Event [Member] \| Chief Investment Officer [Member] \| Share-Based Payment Arrangement, Tranche One [Member] \| Employment Agreement [Member]
Subsequent Event [Line Items]
Shares vested	250,000,000
Subsequent Event [Member] \| Chief Investment Officer [Member] \| Share-Based Payment Arrangement, Tranche Two [Member] \| Employment Agreement [Member]
Subsequent Event [Line Items]
Shares vested	500,000,000
Subsequent Event [Member] \| Chief Investment Officer [Member] \| Share-Based Payment Arrangement, Tranche Three [Member] \| Employment Agreement [Member]
Subsequent Event [Line Items]
Shares vested	1,000,000,000
Subsequent Event [Member] \| Chief Investment Officer [Member] \| Share Based Compensation Award Tranche Four [Member] \| Employment Agreement [Member]
Subsequent Event [Line Items]
Shares vested	2,000,000,000
Subsequent Event [Member] \| Chief Investment Officer [Member] \| Share Based Compensation Award Tranche Five [Member] \| Employment Agreement [Member]
Subsequent Event [Line Items]
Shares vested	3,000,000,000
Subsequent Event [Member] \| Third Party [Member] \| Restricted Stock Units (RSUs) [Member]
Subsequent Event [Line Items]
Shares issued			100,000	155,000
Shares vested			50,000
Subsequent Event [Member] \| Third Party [Member] \| Restricted Stock Units (RSUs) [Member] \| Six Month Anniversaries [Member]
Subsequent Event [Line Items]
Shares vested			50,000
Subsequent Event [Member] \| Third Party [Member] \| Restricted Stock Units (RSUs) [Member] \| Twelve Month Anniversaries [Member]
Subsequent Event [Line Items]
Shares vested			50,000
Subsequent Event [Member] \| Third Party [Member] \| Restricted Stock Units (RSUs) [Member] \| Preferred Stock [Member]
Subsequent Event [Line Items]
Number of shares issued						700,000

STREAMEX LTD. (VIE) (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025	Dec. 31, 2024
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Interest percentage	98.50%
Investement amount	$ 15,000
Other assets held at cost - gold	15,225
Net loss	(46,693)	$ (2,812)
Operating expense	158
Minority interest	256	29	32	$ 17
Streamex Ltd [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Other assets held at cost - gold	15,225
Net loss	155
Minority interest	224
Streamex Ltd [Member] \| Chief Invest Officer [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Variable interst entity	200
Streamex Ltd [Member] \| General Counsel Officers [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Variable interst entity	25
Two Related Party [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Other assets held at cost - gold	$ 225
Related Party [Member]
Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]
Interest percentage	1.50%
Variable interest percentage	1.50%
Minority interest	$ 224

SCHEDULE OF INFORMATION RELATED TO WARRANTS (Details)	3 Months Ended
SCHEDULE OF INFORMATION RELATED TO WARRANTS (Details)	Mar. 31, 2026 $ / shares shares
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 5.00
Number outstanding \| shares	1,647,885
Warrants At 0.3000 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 0.3000
Number outstanding \| shares	11,982
Expiration date	Nov-28
Warrants At 0.9547 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 0.9547
Number outstanding \| shares	577,916
Expiration date	Sep-28
Warrants At 1.7800 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 3.3640
Warrants At 3.3640 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Number outstanding \| shares	117,828
Expiration date	Jul-29
Warrants At 4.0660 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 4.0660
Number outstanding \| shares	25,000
Expiration date	Nov-32
Warrants At 4.4550 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 4.4550
Number outstanding \| shares	107,483
Expiration date	Jun-28
Warrants At 44660 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 4.4660
Number outstanding \| shares	5,580
Expiration date	Apr-29
Warrants At 4.6626 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 4.6626
Number outstanding \| shares	49,550
Expiration date	Mar-29
Warrants At 4.9252 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 4.9252
Number outstanding \| shares	71,593
Expiration date	Mar-29
Warrants At 4.9290 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 4.9290
Number outstanding \| shares	99,243
Expiration date	Jul-28
Warrants At 5.1358 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 5.1358
Number outstanding \| shares	83,270
Expiration date	Jul-28
Warrants At 7.1810 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 7.1810
Number outstanding \| shares	9,846
Expiration date	Jul-28
Warrants At 7.5020 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 7.5020
Number outstanding \| shares	21,369
Expiration date	Aug-28
Warrants At 7.9630 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 7.9630
Number outstanding \| shares	21,709
Expiration date	Jun-27
Warrants At 9.0000 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 9.0000
Number outstanding \| shares	84,390
Expiration date	Jan-29
Warrants At 9.5960 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 9.5960
Number outstanding \| shares	19,118
Expiration date	Aug-28
Warrants At 10.0992 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 10.0992
Number outstanding \| shares	51,705
Expiration date	Sep-28
Warrants At 10.2600 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 10.2600
Number outstanding \| shares	84,296
Expiration date	Sep-28
Warrants At 10.4678 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 10.4678
Number outstanding \| shares	40,417
Expiration date	Oct-28
Warrants At 11.3000 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 11.3000
Number outstanding \| shares	96,198
Expiration date	Nov-28
Warrants At 13.2800 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 13.2800
Number outstanding \| shares	12,500
Expiration date	Jul-26
Warrants At 48.0000 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 48.0000
Number outstanding \| shares	56,892
Expiration date	Nov-27
Warrants At 61.6000 [Member]
Share-Based Payment Arrangement, Option, Exercise Price Range [Line Items]
Exercise price \| $ / shares	$ 61.6000
Number outstanding \| shares	11,982
Expiration date	Nov-28

SCHEDULE OF ACCOUNTS PAYABLE AND ACCRUED EXPENSE (Details) (Parenthetical) - USD ($)
$ in Thousands

Aug. 27, 2025

Mar. 31, 2026

Dec. 31, 2025

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

Prepaid insurance

$ 570

Prepaid insurance premium financing

^[1]

370

$ 916

Other separation-related obligations

$ 779

Premium Finance Agreement [Member]

Collaborative Arrangement and Arrangement Other than Collaborative [Line Items]

$ 2,172

544

1,600

Accounts Payable, Other

1,700

Accounts payable, monthly installments

$ 187

Annual percentage rate

7.48%

[1]

SCHEDULE OF SETTLEMENT (Details) $ in Thousands	3 Months Ended
SCHEDULE OF SETTLEMENT (Details) $ in Thousands	Mar. 31, 2026 USD ($)
Debt Disclosure [Abstract]
Loss on extinguishment of convertible debentures — prepayment premium	$ (3,500)
Gain on derecognition of embedded derivative at settlement	443
Realized loss on extinguishment of convertible debentures	$ (3,057)

Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands

Mar. 31, 2026

Dec. 31, 2025

Current assets:

Cash

$ 6,859

$ 20,316

Sales tax receivable

Marketable securities

23,766

9,706

Prepaid expenses and other assets

15,220

17,339

Total current assets

45,904

71,895

Non-current assets:

Other assets held at cost – gold

15,225

Property and equipment, net

Intangible assets, net

42,418

44,639

Goodwill

69,758

70,984

^[1]

Total non-current assets

127,413

115,648

Total assets

173,317

187,543

Current liabilities:

Accounts payable and accrued expenses, including $907 and $66 to related parties as of March 31, 2026, and December 31, 2025, respectively.

3,179

2,952

Dividends payable

123

121

Convertible debentures, net

38,021

Embedded derivative liability

1,700

Total current liabilities

3,302

42,794

Deferred tax liability

10,669

11,421

Total liabilities

13,971

54,215

Commitments and contingencies (Note 16)

Mezzanine equity

Redeemable Series C 9% Convertible Preferred Stock, $0.001 par value, $1,000 stated value, authorized 4,200 shares, 105 shares issued and outstanding; (liquidation preference of $105; cumulative dividends payable of $123 and $121 as of March 31, 2026, and December 31, 2025, respectively).

105

Stockholders’ equity:

Preferred stock, $0.001 par value, authorized 1,000,000 shares, designated 200 shares of Series A, 600 shares of Series B, 4,200 shares of Series C, 1,400 shares of Series D, 1,000 shares of Series E, 200,000 shares of Series F Preferred Stock and 1 Special Voting Preferred Stock.

Common stock, $0.001 par value, authorized 500,000,000 shares, 97,721,696 and 49,805,275 issued and outstanding as of March 31, 2026, and December 31, 2025, respectively.

Additional paid-in-capital

924,802

850,447

Accumulated other comprehensive (loss) income

(1,102)

814

Accumulated deficit

(764,813)

(718,120)

Total stockholders’ equity attributable to Streamex Corp.

158,985

133,191

Non-controlling interest

256

Total stockholders’ equity

159,241

133,223

Total liabilities, mezzanine equity and stockholders’ equity

173,317

187,543

Restricted Gold [Member]

Current assets:

Other assets held for sale – gold

23,472

Gold [Member]

Current assets:

Other assets held for sale – gold

1,000

Related Party [Member]

Current assets:

Due from related party

$ 11

Stockholders’ equity:

Non-controlling interest

$ 224

[1]

SCHEDULE OF UNOBSERVABLE INPUT (Details) - Fair Value, Inputs, Level 3 [Member]	Feb. 06, 2026	Dec. 31, 2025
Measurement Input Common Stock Price [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivative liability measurement input	3.28	3.03
Measurement Input Indicated Conversion Price [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivative liability measurement input	4.00	4.00
Measurement Input Floor Price [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivative liability measurement input	4.00	4.00
Measurement Input, Prepayment Rate [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivative liability measurement input	100	70
Measurement Input Prepayment Premium [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivative liability measurement input	10	10
Measurement Input Registration Probability [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Derivative liability measurement input	0	0

SCHEDULE OF RESTRICTED STOCK ACTIVITY (Details)	3 Months Ended
SCHEDULE OF RESTRICTED STOCK ACTIVITY (Details)	Mar. 31, 2026 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted	5,903,316
Forfeited
Restricted Stock Units (RSUs) [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Granted	8,868,316
Restricted Stock Units (RSUs) [Member] \| Viral Clear Pharmaceuticals Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Total restricted shares outstanding	2,037,500
Weighted average grant date fair value \| $ / shares	$ 5.36
Granted	8,868,316,000
Granted \| $ / shares	$ 2.91
Vested	(6,123,941,000)
Vested \| $ / shares	$ 3.01
Forfeited	(198,500,000)
Forfeited \| $ / shares	$ 3.21
Total restricted shares outstanding	4,583,375
Total \| $ / shares	$ 3.86
Vested restricted shares	301,500,000
Vested restricted shares, Weighted-Average Grant Date Fair Value Per Share \| $ / shares	$ 3.21
Unvested restricted shares	4,281,875,000
Unvested restricted, Weighted-Average Grant Date Fair Value Per Share \| $ / shares	$ 3.90

Condensed Consolidated Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2026

Mar. 31, 2025

Income Statement [Abstract]

Revenue

Operating expenses:

Research and development

General and administrative

34,254

2,957

Depreciation and amortization

1,492

Total operating expenses

35,746

2,984

Loss from operations

(35,746)

(2,984)

Other income (expense):

Interest expense, net

(12,195)

Realized gain on sale of gold

2,938

Realized gain on marketable securities

484

Change in fair value of marketable securities

(134)

Change in fair value of embedded derivative

497

Realized loss on extinguishment of convertible debentures

(3,057)

Realized loss on investment

(119)

Gain on settlement and forgiveness of debt

199

Other income (expense), net

(15)

Total other income (expense), net

(11,513)

184

Loss before income taxes

(47,259)

(2,800)

Income taxes (benefit)

(565)

Net loss

(46,694)

(2,800)

Non-controlling interest

^[1]

(12)

Net loss attributable to Streamex Corp.

(46,693)

(2,812)

Preferred stock dividend

(2)

Preferred stock deemed dividend

Net loss attributed to Streamex Corp. Common Shareholders

$ (46,695)

$ (2,814)

Net loss per common share, basic

$ (0.27)

$ (0.14)

Net loss per common share, diluted

$ (0.27)

$ (0.14)

Weighted average number of common shares outstanding, diluted

174,590,397

20,787,808

Weighted average number of common shares outstanding, diluted

174,590,397

20,787,808

Comprehensive (Loss) Income:

Change in foreign currency translation adjustments

$ (1,916)

Total comprehensive loss

(48,610)

(2,800)

Comprehensive (loss) income attributable to non-controlling interest

(12)

Comprehensive loss attributable to Streamex Corp.

$ (48,609)

$ (2,812)

[1]	Less than $0.5 thousand

STREAMEX LTD. (VIE)

3 Months Ended

Mar. 31, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

STREAMEX LTD. (VIE)

NOTE 9 – STREAMEX LTD. (VIE)

Overview

Streamex Ltd. (“Streamex Ltd.” or the “VIE”) is a special-purpose entity organized in the Cayman Islands and formed to purchase and hold physical gold and to issue digital GLDY Tokens designed to provide tokenholders exposure to gold and gold-denominated leasing returns. Streamex Ltd. may also lease its gold holdings to generate gold-denominated yield. The Company is involved with Streamex Ltd. through its governance rights and through its economic interests in GLDY Tokens.

Streamex Ltd. began operations during the three months ended March 31, 2026.

Variable Interest Entity Consideration

The Company evaluated Streamex Ltd. under the variable interest entity (“VIE”) model in ASC 810, Consolidation. A legal entity is a VIE if, among other conditions, the holders of the equity investment at risk, as a group, lack the power, through voting rights or similar rights, to direct the activities that most significantly impact the entity’s economic performance. Streamex Ltd. is considered a VIE because the holders of GLDY Tokens (which represent non-voting participating equity interests) lack substantive voting rights and do not have the power to direct the activities that most significantly impact Streamex Ltd.’s economic performance. Voting control resides with the single voting management share, which controls shareholder-level decisions including the appointment and removal of directors, and day-to-day operating authority has been delegated to GLDY ServiceCo, LLC, a consolidated subsidiary of the Company, pursuant to a services agreement. Because Streamex Ltd. is a VIE, the Company evaluated whether it is the primary beneficiary and therefore required to consolidate Streamex Ltd., as discussed below.

Primary Beneficiary Conclusion and Consolidation

The Company evaluated its involvement with Streamex Ltd. under ASC 810, Consolidation, and concluded it is the primary beneficiary and is required to consolidate Streamex Ltd. Under ASC 810-10-25-38, a reporting entity is the primary beneficiary of a VIE only if it has both (i) the power to direct the activities that most significantly impact the VIE’s economic performance and (ii) the obligation to absorb losses or the right to receive benefits from the VIE that could potentially be significant to the VIE. The Company concluded both criteria are met as of March 31, 2026 because it has the power to direct the activities that most significantly impact Streamex Ltd.’s economic performance through its control of the VIE’s governance structure (including the voting management share and related decision rights, as applicable) and the servicer arrangement, and has the obligation to absorb losses or the right to receive benefits that could potentially be significant to the VIE due to its economic interest in the GLDY Tokens.

As of March 31, 2026, the Company held approximately 98.5% of the outstanding GLDY Tokens issued by Streamex Ltd. (approximately $15,000 invested by the Company out of $15,225 total tokens issued). Two related party investors subscribed for an aggregate of approximately $225 in GLDY Tokens during March 2026, representing approximately 1.5% of total tokens outstanding. Accordingly, the Company has consolidated Streamex Ltd. from the date of its formation in the unaudited condensed consolidated financial statements.

Carrying Amounts of Assets and Liabilities of Consolidated VIE

The following table presents the carrying amounts and balance sheet classifications of the significant assets and liabilities of Streamex Ltd. included in the Company’s unaudited condensed consolidated balance sheet as of March 31, 2026. The assets of Streamex Ltd. are generally restricted and can be used only to settle obligations of Streamex Ltd.

Streamex Ltd. assets and liabilities included in the unaudited condensed consolidated balance sheet as of March 31, 2026:


Assets
Other assets held at cost – gold	$	15,225
Cash		60
Total assets	$	15,285

Liabilities
Accounts payable and accrued expenses	$	33
Total liabilities	$	33

During the three months ended March 31, 2026, Streamex Ltd. incurred a net loss of approximately $155, primarily consisting of operating expenses including bank fees, custody-related charges, and digital asset transaction costs. The net loss was funded by capital contributions from the Company and its affiliates (see Note 8 for additional information regarding the gold assets held by Streamex Ltd.).

During March 2026, two officers of the Company subscribed for GLDY Tokens directly with Streamex Ltd.: (i) the Company’s Chief Investment Officer, subscribed for approximately $200 of GLDY Tokens on March 17, 2026, and (ii) the Company’s General Counsel, subscribed for approximately $25 of GLDY Tokens on March 27, 2026. These subscriptions were made on the same terms and at the same per-token price as the Company’s own subscriptions and are related party transactions (see Note 18, Related Party Transactions).

Lack of Recourse / Restrictions

The assets of Streamex Ltd. are generally not available to satisfy the obligations of the Company or its other subsidiaries, and the creditors and tokenholders of Streamex Ltd. generally do not have recourse to the general credit of the Company beyond the assets of Streamex Ltd., except to the limited extent of intercompany balances eliminated in consolidation. The liabilities recognized as a result of consolidating Streamex Ltd. do not represent additional claims on the Company’s general assets.

Maximum Exposure to Loss / Financial Support

The Company’s maximum exposure to loss associated with its involvement with Streamex Ltd. as of March 31, 2026 is limited to the carrying amount of its approximately 98.5% economic interest in the GLDY Tokens and its net interest in Streamex Ltd.’s net assets, which totaled approximately $15,000 at the date of investment. The Company has no arrangements that legally obligate it to provide additional financial support to Streamex Ltd., such as guarantees or liquidity facilities, beyond its role as an investor and service provider. However, the Company funded approximately $158 of Streamex Ltd.’s operating expenses during Q1 2026 through capital contributions from the Company and its affiliates, which are eliminated in consolidation.

Related Party Considerations / Intercompany Eliminations

Streamex Ltd. pays servicing fees to GLDY ServiceCo, LLC, a consolidated subsidiary of the Company, under the applicable servicing arrangement. Because the servicer is a consolidated subsidiary, these servicing fees and related intercompany balances are eliminated in consolidation.

Noncontrolling Interest

As of March 31, 2026, noncontrolling interests in Streamex Ltd. consisted of (i) the single voting management share held by the VIE’s director, which carries governance rights but no material economic interest, and (ii) GLDY Tokens held by two officers of the Company who subscribed as related party investors during March 2026. In aggregate, related party tokenholders held approximately 1.5% of the outstanding GLDY Tokens as of March 31, 2026.

The noncontrolling interest attributable to Streamex Ltd. as of March 31, 2026 was approximately $224, consisting of related party token subscriptions described above, net of the noncontrolling interest’s proportionate share of the VIE’s net loss for the period. The noncontrolling interest is presented within noncontrolling interest on the unaudited condensed consolidated balance sheet and in the unaudited condensed consolidated statements of operations. See Note 15 for the noncontrolling interest rollforward and attribution tables.

Ongoing Assessment

The Company reassesses its primary beneficiary conclusion on an ongoing basis in accordance with ASC 810 whenever changes in facts and circumstances occur that could affect the determination of whether either criterion under ASC 810 continues to be met. Changes that could affect the primary beneficiary assessment include, but are not limited to, changes in GLDY Token ownership (including issuance, redemption, or transfer of GLDY Tokens to unrelated third parties that could affect the significance of the Company’s economic exposure to the VIE), modifications of governing documents or fee arrangements, changes in ownership of the management share, or replacement of the affiliated servicer by an unrelated party. As of March 31, 2026, no changes in facts or circumstances have occurred that would alter the Company’s conclusion.

SUMMARY OF WARRANT ACTIVITY (Details)	3 Months Ended
SUMMARY OF WARRANT ACTIVITY (Details)	Mar. 31, 2026 $ / shares shares
Equity [Abstract]
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, beginning \| shares	473,772
Weighted-Average Exercise Price, Outstanding \| $ / shares	$ 5.00
Weighted-Average Remaining Contractual Term, Outstanding	1 year 10 months 24 days
Forfeited Expired \| shares
Weighted-Average Exercise Price, Forfeited/expired \| $ / shares
Share-Based Compensation Arrangement by Share-Based Payment Award, Non-Option Equity Instruments, Ending \| shares	473,772
Weighted-Average Exercise Price, Outstanding \| $ / shares	$ 5.00
Weighted-Average Remaining Contractual Term, Outstanding	1 year 7 months 6 days
Exercisable warrants \| shares	473,772
Weighted-Average Exercise Price, Exercisable \| $ / shares	$ 5.00
Weighted-Average Remaining Contractual Term, Exercisable	1 year 7 months 6 days

SCHEDULE OF NON-CONTROLLING INTEREST (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2026

Mar. 31, 2025

Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]

Net loss

$ (155)

$ 75

Noncontrolling interest’s weighted-average ownership percentage

0.01%

16.00%

Net loss attributable to non-controlling interest

^[1]

$ (1)

$ 12

Viral Clear Pharmaceuticals Inc [Member]

Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]

Net loss

^[1]

Noncontrolling interest’s weighted-average ownership percentage

30.00%

32.00%

Net loss attributable to non-controlling interest

^[1]

Bio Sig AI Sciences Inc [Member]

Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]

Net loss

$ 75

Noncontrolling interest’s weighted-average ownership percentage

16.00%

Net loss attributable to non-controlling interest

^[1]

$ 12

Streamex Ltd [Member]

Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]

Net loss

$ (155)

Noncontrolling interest’s weighted-average ownership percentage

0.20%

Net loss attributable to non-controlling interest

^[1]

$ (1)

[1]	Less than $0.5 thousand

- Definition

Amount of Net Income (Loss) attributable to noncontrolling interest.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 7
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-7

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 205
-SubTopic 20
-Name Accounting Standards Codification
-Section 50
-Paragraph 5A
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483499/205-20-50-5A

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 323
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 3
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481687/323-10-50-3

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-6

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 8
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-8

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 250
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 9
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483443/250-10-50-9

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 944
-SubTopic 220
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(17))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147477250/944-220-S99-1

Reference 8: http://www.xbrl.org/2009/role/commonPracticeRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482765/220-10-50-6

Reference 9: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 810
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1A
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481203/810-10-50-1A

Reference 10: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Topic 810
-SubTopic 10
-Section 55
-Paragraph 4J
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147481175/810-10-55-4J

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1A

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 220
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 1B
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482790/220-10-45-1B

+ Details

MARKETABLE SECURITIES

3 Months Ended

Mar. 31, 2026

Investments, Debt and Equity Securities [Abstract]

MARKETABLE SECURITIES

NOTE 7 – MARKETABLE SECURITIES

Exchange-Traded Funds

The Company’s marketable securities consist of exchange-traded funds (“ETFs”) holding short-term U.S. Treasury securities and investment-grade corporate debt instruments. As of March 31, 2026, the portfolio was composed of four ETFs: iShares 0-3 Month Treasury Bond ETF (SGOV), SPDR Portfolio Short-Term Treasury ETF (SPTS), Vanguard Short-Term Treasury Index ETF (VGSH), and Vanguard Short-Term Corporate Bond ETF (VCSH), each representing approximately 25% of the total portfolio. These securities are held in a brokerage account and are classified as equity securities measured at fair value with changes in fair value recognized in earnings, in accordance with ASC 321, Investments — Equity Securities.

Fair value is determined using quoted market prices in active markets and, accordingly, all marketable securities are classified within Level 1 of the ASC 820 fair value hierarchy.

During the three months ended March 31, 2026, the Company purchased approximately $23,900 of marketable securities on February 26, 2026. No ETF securities were sold during the period; therefore, no realized gains or losses were recognized. As of March 31, 2026, the aggregate fair value of the ETF portfolio was approximately $23,766 against a cost basis of $23,900, resulting in a net unrealized loss of approximately $(134), which related entirely to equity securities still held as of March 31, 2026 and is included in “Change in fair value of marketable securities” in the unaudited condensed consolidated statements of operations. No impairment charges were recognized during the period. During the three months ended March 31, 2026, the Company earned dividend income and interest income on sweep balances totaling approximately $71, which is included in “Other income (expense), net” in the unaudited condensed consolidated statements of operations.

As of December 31, 2025, the Company held no ETF investments.

Empress Royalty Corp.

On December 9, 2025, the Company entered into a share purchase agreement with Terra Capital Natural Resources Fund Pty Ltd to acquire 12,671,297 common shares of Empress Royalty Corp. (“Empress”), representing approximately 9.9% of Empress’s outstanding common shares. Empress is listed on the TSX Venture Exchange and OTCQX.

As consideration, the Company issued 2,443,750 restricted shares of its common stock on December 12, 2025, the date ownership transferred. The investment was initially recognized at $10,533, based on the fair value of 2,443,750 Streamex shares issued at $4.31 per share on December 12, 2025. The Company does not have significant influence over Empress.

As of December 31, 2025, the fair value of the Empress investment was approximately $9,706, with the resulting unrealized loss of $(827) recognized in earnings during the year ended December 31, 2025. In January 2026, the Company sold all of its shares in Empress Royalty Corp. for gross proceeds of approximately $10,190, resulting in a realized gain of $484 measured from the December 31, 2025 fair value. The realized gain is included in “Realized gain on marketable securities” in other income (expense) in the unaudited condensed consolidated statements of operations. As the investment was disposed of prior to March 31, 2026, no unrealized gains or losses on the Empress investment were recognized during the three months ended March 31, 2026, and no impairment charges were recorded during any period in which the investment was held. As of March 31, 2026, the Company held no investment in Empress Royalty Corp.

COMMITMENTS AND CONTINGENCIES

3 Months Ended

Mar. 31, 2026

Commitments and Contingencies Disclosure [Abstract]

COMMITMENTS AND CONTINGENCIES

NOTE 16 — COMMITMENTS AND CONTINGENCIES

Tokenized Yield Partnership Agreement

Overview

On September 8, 2025, the Company entered into a Tokenized Yield Partnership Agreement (the “Token Agreement”) with Monetary Metals & Co. (“MM”), a Delaware corporation, establishing an exclusive, multi-year strategic partnership to design, launch, and distribute blockchain-based financial products that tokenize the yield generated from MM’s precious-metal lease and bond programs. The Token Agreement commenced on September 8, 2025 and continues for an initial term of three years, subject to automatic one-year renewal periods unless terminated in accordance with its terms.

For additional information regarding the gold assets held by Streamex Ltd. and the related VIE disclosures, see Notes 8 and 9.

Exclusivity and Performance Conditions

For at least three years, MM agreed not to engage with any other party to tokenize the yield or other financial attributes of its precious-metal lease or bond products, and the Company agreed not to partner with any third party to tokenize yield derived from precious-metal leases, in each case subject to specified volume-based performance conditions. To maintain exclusivity, the Company must supply at least 10% of the total leased ounces presented by MM each quarter that meet defined criteria, including minimum insurance standards, a net yield of at least 3% per annum after origination fees, and compliance with restrictions on counterparties and jurisdictions. Failure to meet these thresholds, after a 90-day cure period, results in loss of exclusivity but does not obligate the Company to commit capital or continue participation.

Consulting Services Agreement

On February 4, 2026, the Company entered into a consulting agreement with an independent third party to provide advisory and capital markets related services in connection with the Company’s GLDY Token program. The agreement has an initial term of six months and provides for a fixed consulting fee of $4,000, as well as potential transaction-based fees contingent upon the completion of certain activities during the term. The full $4,000 base fee was paid during the three months ended March 31, 2026. As of March 31, 2026, the unamortized portion of $2,785 is included in prepaid expenses and other assets on the unaudited condensed consolidated balance sheet and is being recognized ratably over the service period. No transaction-based fees were earned or payable during the period.

Litigation

We may be subject at times to other legal proceedings and claims, which arise in the ordinary course of our business. Although occasional adverse decisions or settlements may occur, the Company believes that the final disposition of such matters should not have a material adverse effect on its financial position, results of operations or liquidity.

In November 2025, a former advisor filed a Notice of Civil Claim in the Supreme Court of British Columbia against the Company, its wholly owned subsidiary Streamex Exchange Corporation, and certain current officers and directors. The claim alleges, among other things, breach of contract, unjust enrichment, and civil conspiracy in connection with alleged agreements relating to equity interests in Streamex Exchange Corporation prior to the Company’s acquisition of that entity. The plaintiff seeks, among other relief, specific performance, equitable compensation, and damages.

The Company disputes the claims and intends to defend the matter vigorously. As of March 31, 2026, no liability has been recorded in the unaudited condensed consolidated financial statements related to this matter, as management, after consultation with legal counsel, believes that a loss is not probable. The matter is in a preliminary stage and, as a result, the Company is unable to reasonably estimate the possible loss or range of loss, if any, associated with this matter at this time.

SCHEDULE OF RECURRING BASIS FAIR VALUE MEASUREMENTS (Details) - USD ($) $ in Thousands	Mar. 31, 2026	Feb. 26, 2026	Dec. 31, 2025
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Embedded derivative liabilities – Yorkville Debentures	$ 1,203
Marketable securities	23,766	$ 23,900	$ 9,706
Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Embedded derivative liabilities – Yorkville Debentures			1,700
Fair Value, Inputs, Level 1 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Marketable securities	$ 23,766		$ 9,706

NATURE OF OPERATIONS (Details Narrative) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2026	Dec. 31, 2025
Other assets non current	$ 15,225
Variable interest entity acquired		$ 5,900
GLDY ServiceCo, LLC [Member]
Other assets non current	$ 15,225
Variable interest entity acquired, percentage	98.50%
Variable interest entity acquired	$ 225
Viral Clear [Member]
Equity method investment, ownership percentage	70.00%
BioSig AI Sciences, Inc. [Member]
Equity method investment, ownership percentage	84.00%	84.00%

FAIR VALUE MEASUREMENTS (Tables)

3 Months Ended

Mar. 31, 2026

Fair Value Disclosures [Abstract]

SCHEDULE OF ASSETS MEASURED AT FAIR VALUE ON NONRECURRING BASIS

Assets that are measured at fair value and classified as level 3 on a nonrecurring basis are as follows:

Description	May 28, 2025
Trade name	$	5,100
Developed technology	$	40,000
Legal and compliance framework	$	2,400
Fair value of intangible assets	$	2,400

Goodwill	$	70,435

SCHEDULE OF UNOBSERVABLE INPUT

Prior to settlement on February 6, 2026, the embedded conversion derivative was valued using a Monte Carlo simulation model incorporating the following significant unobservable inputs (Level 3):

SCHEDULE OF UNOBSERVABLE INPUT

	2/6/2026			12/31/2025
Unobservable / key assumption	Remeasurement			Remeasurement
Common stock price	$	3.28		$	3.03
Indicated conversion price	$	4.00		$	4.00
Floor price	$	4.00		$	4.00
Prepayment probability		100	%		70	%
Prepayment premium		10	%		10	%
Registration probability		0	%		0	%

SCHEDULE OF DERIVATIVE INSTRUMENTS ON EARNINGS

The following table presents the impact of the Company’s derivative instruments on earnings for the three months ended March 31, 2026:

		Amount
Change in fair value of embedded derivative		$	497

SCHEDULE OF FAIR VALUE MEASUREMENTS EMBEDDED DERIVATIVE LIABILITY

Rollforward of Level 3 Recurring Fair Value Measurements – Embedded Derivative Liabilities:

	Amount
Balance as of December 31, 2025	$	1,700
Change in fair value		(497	)
Settlements		(1,203	)
Balance as of March 31, 2026	$	-

SCHEDULE OF RECURRING BASIS FAIR VALUE MEASUREMENTS

The following table presents information about the Company’s financial instruments measured at fair value on a recurring basis as of March 31, 2026 (in thousands):

Description	Level		March 31, 2026		December 31, 2025
Embedded derivative liabilities – Yorkville Debentures		3	$	-	$	1,700
Marketable securities		1	$	23,766	$	9,706

SCHEDULE OF RELATED TO WARRANTS (Details)	3 Months Ended
SCHEDULE OF RELATED TO WARRANTS (Details)	Mar. 31, 2026 $ / shares shares
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Warrants exercise price \| $ / shares	$ 5.00
Warrants rights outstanding \| shares	473,772
Range One [Member] \| Viral Clear Pharmaceuticals Inc [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Expiration date	November 2027

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(v)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (f)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (l)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 1D
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-1D

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 35
-Paragraph 3
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480483/718-10-35-3

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 14: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 15: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 16: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 17: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 18: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 19: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 20: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 21: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(04)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 22: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 23: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(ii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 24: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 25: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(01)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 26: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(02)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 27: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(iii)(03)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 28: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (d)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 29: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

Reference 30: http://www.xbrl.org/2003/role/disclosureRef
-Topic 718
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (e)(2)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480429/718-10-50-2

+ Details

SCHEDULE OF FAIR VALUE MEASUREMENTS EMBEDDED DERIVATIVE LIABILITY (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2026 USD ($)
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Balance as of December 31, 2025	$ 1,700
Balance as of March 31, 2026
Fair Value, Inputs, Level 3 [Member]
Fair Value, off-Balance-Sheet Risks, Disclosure Information [Line Items]
Balance as of December 31, 2025	1,700
Change in fair value	(497)
Settlements	(1,203)
Balance as of March 31, 2026

SCHEDULE OF CHANGES IN NON-CONTROLLING INTEREST (Details) - USD ($)
$ in Thousands

3 Months Ended

Mar. 31, 2026

Mar. 31, 2025

Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]

Balance, January 1, 2025

$ 32

$ 17

Issuance of equity to noncontrolling interest holders

225

Net income (loss) attributable to non-controlling interest

^[1]

(1)

Balance, March 31, 2025

256

Viral Clear Pharmaceuticals Inc [Member]

Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]

Balance, January 1, 2025

(171)

Issuance of equity to noncontrolling interest holders

Net income (loss) attributable to non-controlling interest

^[1]

Balance, March 31, 2025

(171)

Bio Sig AI Sciences Inc [Member]

Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]

Balance, January 1, 2025

203

188

Issuance of equity to noncontrolling interest holders

Net income (loss) attributable to non-controlling interest

^[1]

Balance, March 31, 2025

203

200

Streamex Ltd [Member]

Consolidation, Less than Wholly Owned Subsidiary, Parent Ownership Interest, Effects of Changes, Net [Line Items]

Balance, January 1, 2025

Issuance of equity to noncontrolling interest holders

225

Net income (loss) attributable to non-controlling interest

^[1]

(1)

Balance, March 31, 2025

$ 224

[1]	Less than $0.5 thousand

- Definition

Amount of equity (deficit) attributable to noncontrolling interest. Excludes temporary equity.

+ References

+ Details

- Definition

Amount of Net Income (Loss) attributable to noncontrolling interest.

+ References

+ Details

GOODWILL AND INTANGIBLE ASSETS

3 Months Ended

Mar. 31, 2026

Intangible Asset, Goodwill and Other [Abstract]

GOODWILL AND INTANGIBLE ASSETS

NOTE 5 – GOODWILL AND INTANGIBLE ASSETS

Goodwill

The following table shows the changes in the carrying amount of goodwill for the period:

SCHEDULE OF CARRYING AMOUNT OF GOODWILL

Goodwill as of December 31, 2025 (1)	$	70,984
Acquisition		-
Impairment		-
Foreign currency translation adjustment		(1,226	)
Goodwill as of March 31, 2026	$	69,758

During the three months ended March 31, 2026, the Company evaluated the existence of any indicators of impairment in accordance with ASC 350, Intangibles—Goodwill and Other. Based on the qualitative assessment performed, management concluded that the combination of factors considered did not result in a triggering event requiring a quantitative impairment test. Based on the assessment, there was no goodwill impairment recognized in the three months ended March 31, 2026.

Intangible Assets

Intangible assets consist of trade name, developed technology, legal and compliance framework, and patents, and are initially recorded at fair value. Long-lived intangible assets are amortized over their estimated useful lives in a method reflecting the pattern in which the economic benefits are consumed or amortized on a straight-line basis if such pattern cannot be reliably determined. The Company evaluates its finite-lived intangible assets for impairment in accordance with ASC 360-10-35 whenever events or changes in circumstances indicate that the carrying amount of an asset or asset group may not be recoverable. During the three months ended March 31, 2026, the Company evaluated whether any such triggering events existed, including consideration of changes in the business environment, market conditions, and asset utilization. Based on this assessment, management concluded that no triggering events occurred and that the carrying amounts of the Company’s finite-lived intangible assets were recoverable. Accordingly, no impairment charges were recorded for the three months ended March 31, 2026 or 2025.

The following summarizes the Company’s intangible assets as of March 31, 2026 and December 31, 2025:

SCHEDULE OF INTANGIBLE ASSETS

	March 31,			December 31,
	2026			2025
Trade name (1)	$	5,100		$	5,100
Developed technology (1)		40,000			40,000
Legal and compliance framework (1)		2,400			2,400
Patents		380			380
Total		47,880			47,880
Foreign currency translation adjustment		(456	)		371
Accumulated amortization:
Trade name		(425	)		(303	)
Developed technology		(4,162	)		(2,975	)
Legal and compliance framework		(285	)		(204	)
Patents		(134	)		(130	)
Total accumulated amortization		(5,006	)		(3,612	)
Intangible assets, net	$	42,418		$	44,639

Amortization expenses for total intangible assets were $1,479 and $3 for the three months ended March 31, 2026 and 2025, respectively. Amortization expenses for trade name, developed technology, legal and compliance framework and patents was $128, $1,260, $86 and $5, respectively, for the three months ended March 31, 2026. Amortization expenses for trade name, developed technology, legal and compliance framework and patents was $0, $0, $0 and $3, respectively, for the three months ended March 31, 2025. The weighted-average useful lives of total intangibles, trade name, developed technology, legal and compliance framework and patents were 7.4 years, 9.2 years, 7.2 years, 6.2 years and 13.5 years, respectively, as of March 31, 2026.

Expected future amortization expense of intangible assets as of March 31, 2026, is as follows:


Remainder 2026	$	4,362
2027		5,816
2028		5,816
2029		5,816
2030		5,816
Thereafter		14,792
Total	$	42,418

NATURE OF OPERATIONS

3 Months Ended

Mar. 31, 2026

Organization, Consolidation and Presentation of Financial Statements [Abstract]

NATURE OF OPERATIONS

NOTE 1 – NATURE OF OPERATIONS

Business and organization

Streamex Corp. (the “Company”, “we”, “us” and “our”) is a technology company with two principal lines of business: (i) digital infrastructure focused on the tokenization and exchange of real-world assets and other commodity-linked financial products and (ii) biomedical technology focused on advanced signal acquisition and processing solutions in electrophysiology through our PURE EP™ platform. On May 28, 2025, the Company acquired Streamex Exchange Corporation (“Streamex Exchange”), a software development company based in Vancouver, British Columbia. In connection with this strategic expansion, on September 12, 2025, the Company changed its corporate name from BioSig Technologies, Inc. to Streamex Corp., and effective September 12, 2025, the Company’s common stock began trading on The Nasdaq Capital Market under the ticker symbol “STEX” (formerly “BSGM”).

On May 28, 2025, the Company completed the acquisition of Streamex Exchange pursuant to that certain Share Purchase Agreement dated as of May 23, 2025 (as amended on May 27, 2025, the “Share Purchase Agreement”) by and among the Company, BST Sub ULC, an unlimited liability company organized under the laws of the Province of British Columbia and a wholly owned subsidiary of the Company (“ExchangeCo”), 1540875 B.C. Ltd., a British Columbia company and a wholly owned subsidiary of the Company (“Callco”), the shareholders of Streamex Exchange, and 1540873 B.C. Ltd., as trustee (the “Trustee”) under the exchange rights agreement entered into among the Company, ExchangeCo, Callco, and the Trustee (the “Exchange Rights Agreement”).

The Company continues to evaluate opportunities for its subsidiaries ViralClear Pharmaceuticals, Inc. (“ViralClear”) and BioSig AI Sciences, Inc. (“BioSig AI”). As of March 31, 2026 and December 31, 2025, the Company held a majority interest of approximately 70% in ViralClear. As of March 31, 2026, and December 31, 2025, the Company held a majority interest of approximately 84% in BioSig AI.

During the three months ended March 31, 2026, the Company, through Streamex Ltd., a Cayman Islands special-purpose entity consolidated as a variable interest entity, acquired approximately $15,225 of gold bullion to support the GLDY Token program. As of March 31, 2026, the Company held approximately 98.5% of outstanding GLDY Tokens. Two related party officers of the Company subscribed for an aggregate of approximately $225 of GLDY Tokens during March 2026. The Company also formed GLDY ServiceCo, LLC, a wholly owned subsidiary that acts as servicer to Streamex Ltd. under a servicing arrangement.

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended
	Mar. 31, 2026	Mar. 31, 2025
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (46,694,000)	$ (2,800,000)
Adjustments to reconcile net loss to cash used in operating activities:
Depreciation and amortization	1,492,000	21,000
Amortization of debt discount and issuance costs	11,979,000
Gain on settlement and extinguishment of accounts payable		199,000
Non-cash lease expense		41,000
Realized gain on sale of gold	(2,938,000)
Realized gain on marketable securities	(484,000)
Change in fair value of marketable securities	134,000
Change in fair value of embedded derivative	(497,000)
Realized loss on extinguishment of convertible debentures	3,057,000
Realized loss on investment	119,000
Stock-based compensation expense	25,370,000	2,074,000
Deferred income taxes	(565,000)
Changes in operating assets and liabilities:
Accounts receivable	11,000
Lease receivables		17,000
Sales tax receivable	(9,000)
Prepaid expenses and other assets	(1,934,000)	(70,000)
Accounts payable and accrued expenses	780,000	(555,000)
Operating lease liabilities		(42,000)
Net cash used in operating activities	(10,179,000)	(1,115,000)
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of marketable securities	(23,900,000)
Proceeds from the sale of marketable securities	10,190,000
Proceeds from the sale of non-marketable equity investments	25,000
Proceeds from sale of gold	26,410,000
Purchase of gold assets	(14,225,000)
Net cash used in investing activity	(1,500,000)
CASH FLOWS FROM FINANCING ACTIVITIES:
Proceeds from sale of common stock under at-the-market offerings, net of issuance costs		3,882,000
Proceeds from sale of common stock and warrants, net of issuance costs		818,000
Repayment of finance obligation	(546,000)
Net proceeds from issuance of common stock in underwritten public offering	37,184,000
Proceeds from issuance of equity in subsidiary to non-controlling interest holders	225,000
Repayment of convertible debentures	(38,500,000)
Net cash (used in) provided by financing activities	(1,637,000)	4,700,000
Effect of exchange rate change on cash	(141,000)
Net (decrease) increase in cash	(13,457,000)	3,585,000
Cash, beginning of the period	20,316,000	142,000
Cash, end of the period	6,859,000	3,727,000
Supplemental disclosures of cash flow information:
Cash paid during the period for interest	403,000
Cash paid during the period for income taxes
Noncash investing and financing activities:
Common stock issued in settlement of accounts payable		189,000
Dividend payable on preferred stock charged to additional paid-in-capital	2,000	2,000
Conversion of convertible debentures into common stock	$ 15,760,000

SCHEDULE OF ESTIMATED GRANT DATE FAIR VALUE (Details) (Parenthetical)	3 Months Ended
	Mar. 31, 2026 $ / shares
Share-Based Payment Arrangement [Member]
Share-Based Compensation Arrangement by Share-Based Payment Award [Line Items]
Share based compensation, price per share	$ 3.56

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

Condensed Consolidated Balance Sheets (Parenthetical) - USD ($) $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2026	Dec. 31, 2025
Preferred stock, par value	$ 0.001	$ 0.001
Preferred stock, shares authorized	1,000,000	1,000,000
Preferred stock, voting rights	1	1
Common stock, par value	$ 0.001	$ 0.001
Common stock, shares authorized	500,000,000	500,000,000
Common stock, shares issued	97,721,696	49,805,275
Common stock, shares outstanding	97,721,696	49,805,275
Series C 9% Convertible Preferred Stock [Member]
Temporary equity, par value	$ 0.001	$ 0.001
Temporary equity, stated value	$ 1,000	$ 1,000
Temporary equity, shares authorized	4,200	4,200
Temporary equity, shares issued	105	105
Temporary equity, shares outstanding	105	105
Liquidation preference	$ 105	$ 105
Cumulative dividends	$ 123	$ 121
Series A Preferred Stock [Member]
Preferred stock, shares authorized	200	200
Series B Preferred Stock [Member]
Preferred stock, shares authorized	600	600
Series C Preferred Stock [Member]
Preferred stock, shares authorized	4,200	4,200
Series D Preferred Stock [Member]
Preferred stock, shares authorized	1,400	1,400
Series E Preferred Stock [Member]
Preferred stock, shares authorized	1,000	1,000
Series F Preferred Stock [Member]
Preferred stock, shares authorized	200,000	200,000
Related Party [Member]
Accounts payable and accrued expenses, related parties	$ 907	$ 66

BUSINESS ACQUISITION (Tables)

3 Months Ended

Mar. 31, 2026

Business Combination, Asset Acquisition, Transaction between Entities under Common Control, and Joint Venture Formation [Abstract]

SCHEDULE OF TANGIBLE AND IDENTIFIABLE INTANGIBLE ASSETS ACQUIRED AND LIABILITIES ASSUMED

The final allocation of the purchase consideration is as follows:

Amount Recognized as of the Acquisition Date (In Thousands)
Assets acquired
Cash	$	366
Due from related party		11
Sales tax receivable		14
Prepaid expenses		22
Trade name		5,100
Developed technology		40,000
Legal and compliance framework		2,400
Goodwill		70,435
Total assets acquired	$	118,348
Liabilities assumed
Accounts payable and accrued expenses	$	(262	)
Deferred tax liability		(12,588	)
Total liabilities assumed	$	(12,850	)
Net assets acquired		105,498

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Policies)

3 Months Ended

Mar. 31, 2026

Accounting Policies [Abstract]

Basis of Presentation

Basis of Presentation

Basis of Consolidation

Basis of Consolidation

Use of estimates

Use of estimates

Foreign Currency Translation

Foreign Currency Translation

Marketable Securities

Marketable Securities

Gold Assets

Gold Assets

Concentration of Assets

Concentration of Assets

Net Income (loss) Per Common Share

Net Income (loss) Per Common Share

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

	March 31,		March 31,
	2026		2025
Series C convertible preferred stock		434,845		564,234
Options to purchase common stock		2,921,000		2,486,000
Performance-based restricted stock units		1,500,000		-
Warrants to purchase common stock		1,647,885		5,577,260
Restricted stock units to acquire common stock		4,583,375		1,160,830
Totals		11,087,105		9,788,324

Recently adopted accounting pronouncements

Recently adopted accounting pronouncements

Recently issued accounting pronouncements not yet adopted

Recently issued accounting pronouncements not yet adopted

FAIR VALUE MEASUREMENTS

3 Months Ended

Mar. 31, 2026

Fair Value Disclosures [Abstract]

FAIR VALUE MEASUREMENTS

NOTE 12 – FAIR VALUE MEASUREMENTS

The Company measures certain financial instruments at fair value on a recurring basis in accordance with ASC 820, Fair Value Measurement. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

Assets and liabilities that are measured at fair value on a nonrecurring basis relate primarily to tangible property and equipment, goodwill and other intangible assets, which are remeasured when the derived fair value is below carrying value in the consolidated balance sheets. For these assets, the Company does not periodically adjust carrying value to fair value except in the event of impairment. If it is determined that impairment has occurred, the carrying value of the asset is reduced to fair value and the difference is included in impairments and other charges, net in the consolidated statements of operations.

Nonrecurring Level 3 Fair Value Measurements

Assets that are measured at fair value and classified as level 3 on a nonrecurring basis are as follows:

Description	May 28, 2025
Trade name	$	5,100
Developed technology	$	40,000
Legal and compliance framework	$	2,400
Fair value of intangible assets	$	2,400

Goodwill	$	70,435

All these assets were measured at the acquisition dates in conjunction with the Streamex Exchange acquisition. See Note 4, Business Acquisition, for additional information regarding the purchase price allocation and valuation methodologies.

Derivative Liabilities – Recurring Fair Value Measurements (Embedded Conversion Options)

The embedded conversion options associated with the Company’s secured convertible debentures were bifurcated and accounted for as derivative liabilities under ASC 815. The derivative liabilities were measured at fair value upon issuance of each debenture tranche (November 4, 2025 and December 17, 2025) and subsequently remeasured at fair value on a recurring basis through settlement on February 6, 2026. See Note 11, Convertible Debentures and Related Derivative Instruments, for information regarding the terms of the Convertible Debentures, the bifurcation analysis, settlement mechanics, and extinguishment accounting.

The Company estimated the fair value of the embedded conversion options using a Monte Carlo simulation model within a “with-and-without” framework, which isolates the value of the holder’s conversion option by comparing the fair value of the debentures with and without the embedded conversion feature. The Monte Carlo model was designed to capture the path-dependent and non-linear features of the conversion option, including variable conversion pricing, contractual floor prices, amortization mechanics, optional prepayment features, and management’s expectations regarding conversion and repayment behavior. Because the valuation utilized significant unobservable inputs, the derivative liabilities were classified as Level 3 within the fair value hierarchy.

Prior to settlement on February 6, 2026, the embedded conversion derivative was valued using a Monte Carlo simulation model incorporating the following significant unobservable inputs (Level 3):

SCHEDULE OF UNOBSERVABLE INPUT

	2/6/2026			12/31/2025
Unobservable / key assumption	Remeasurement			Remeasurement
Common stock price	$	3.28		$	3.03
Indicated conversion price	$	4.00		$	4.00
Floor price	$	4.00		$	4.00
Prepayment probability		100	%		70	%
Prepayment premium		10	%		10	%
Registration probability		0	%		0	%

The February 6, 2026, valuation incorporated management’s assessment that optional prepayment was the most likely outcome and weighted prepayment and non-prepayment scenarios accordingly. Registration-dependent conversion scenarios were assigned a zero probability, as registration effectiveness was not expected.

The fair value of the derivative liabilities is most sensitive to changes in the Company’s stock price, expected volatility, and assumptions regarding the timing and likelihood of prepayment. An increase in expected volatility or stock price would generally increase the fair value of the derivative liability, while an increase in the probability of early prepayment would generally decrease the fair value. Due to the path-dependent nature of the valuation, quantitative sensitivity analyses are not presented.

During the three months ended March 31, 2026, the Company recognized a gain of $497 related to changes in the fair value of the embedded derivative liabilities prior to settlement on February 6, 2026. On settlement, the Company derecognized the remaining embedded derivative liability of $1,203, resulting in a gain on derecognition of $443 included in “Realized loss on extinguishment of convertible debentures” in the unaudited condensed consolidated statements of operations. See Note 11 for the complete extinguishment accounting.

The following table presents the impact of the Company’s derivative instruments on earnings for the three months ended March 31, 2026:

		Amount
Change in fair value of embedded derivative		$	497

Rollforward of Level 3 Recurring Fair Value Measurements – Embedded Derivative Liabilities:

	Amount
Balance as of December 31, 2025	$	1,700
Change in fair value		(497	)
Settlements		(1,203	)
Balance as of March 31, 2026	$	-

Investment in Empress Royalty Corp.

The Company’s investment in Empress Royalty Corp. is measured at fair value each reporting period based on quoted market prices in active markets. This represents a Level 1 measurement within the fair value hierarchy. The fair value is based on quoted prices on the TSX Venture Exchange (principal market), translated into U.S. dollars using the spot exchange rate at the measurement date.

In January 2026, the Company sold all of its shares in Empress Royalty Corp. for gross proceeds of approximately $10,190, resulting in a realized gain on marketable securities of $484, which is included in other income (expense) in the unaudited condensed consolidated statements of operations. As of March 31, 2026, the Company held no investment in Empress Royalty Corp. See Note 7, Marketable Securities, for additional information.

Exchange-Traded Funds

The Company’s investments in exchange-traded funds (“ETFs”) holding short-term U.S. Treasury securities and investment-grade corporate debt instruments are measured at fair value each reporting period based on quoted market prices in active markets. This represents a Level 1 measurement within the fair value hierarchy.

Recurring Fair Value Measurements

The following table presents information about the Company’s financial instruments measured at fair value on a recurring basis as of March 31, 2026 (in thousands):

Description	Level		March 31, 2026		December 31, 2025
Embedded derivative liabilities – Yorkville Debentures		3	$	-	$	1,700
Marketable securities		1	$	23,766	$	9,706

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (bbb)(1)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 107
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-107

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 55
-Paragraph 100
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482078/820-10-55-100

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (c)(3)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2E
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2E

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (f)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (e)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 10: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 6A
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-6A

Reference 11: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (h)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 12: http://www.xbrl.org/2003/role/disclosureRef
-Topic 820
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 2
-Subparagraph (g)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482106/820-10-50-2

Reference 13: http://www.xbrl.org/2003/role/disclosureRef
-Topic 940
-SubTopic 820
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (a)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478119/940-820-50-1

+ Details

SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (Tables)

3 Months Ended

Mar. 31, 2026

Accounting Policies [Abstract]

SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE

Potentially dilutive securities excluded from the computation of basic and diluted net income (loss) per share are as follows:

	March 31,		March 31,
	2026		2025
Series C convertible preferred stock		434,845		564,234
Options to purchase common stock		2,921,000		2,486,000
Performance-based restricted stock units		1,500,000		-
Warrants to purchase common stock		1,647,885		5,577,260
Restricted stock units to acquire common stock		4,583,375		1,160,830
Totals		11,087,105		9,788,324

Condensed Consolidated Statements of Changes in Stockholders' Equity (Unaudited) - USD ($)
$ in Thousands

Common Stock [Member]

Additional Paid-in Capital [Member]

Retained Earnings [Member]

AOCI Attributable to Parent [Member]

Noncontrolling Interest [Member]

Total

Balance at Dec. 31, 2024

$ 17

$ 253,784

$ (255,345)

$ 17

$ (1,527)

Balance, shares at Dec. 31, 2024

17,239,096

Stock based compensation

$ 2

2,072

2,074

Stock based compensation, shares

1,663,543

Exercise of warrants

^[1]

Exercise of warrants, shares

48,996

Preferred stock dividend

(2)

Net (loss) income

(2,812)

(2,800)

Sale of common stock under at-the- market offering, net of transaction costs

$ 4

3,878

3,882

Sale of common stock under-at-the market offering, net of transaction costs, shares

4,403,166

Sale of common stock and warrants

$ 1

817

818

Sale of common stock and warrants, shares

758,514

Common stock issued to settle accounts payable

^[1]

189

Common stock issued to settle accounts payable, shares

135,000

Balance at Mar. 31, 2025

$ 24

260,738

(258,157)

2,634

Balance, shares at Mar. 31, 2025

24,248,315

Balance at Dec. 31, 2025

$ 50

850,447

(718,120)

$ 814

133,223

Balance, shares at Dec. 31, 2025

49,805,275

Stock based compensation

$ 6

21,455

21,461

Stock based compensation, shares

6,123,941

Exercise of warrants

^[1]

Exercise of warrants, shares

54,647

Net proceeds from issuance of common stock in underwritten public offering

$ 13

37,171

37,184

Net proceeds from issuance of common stock in underwritten public offering, shares

13,416,667

Conversion of exchangeable shares into common stock

$ 25

(25)

Conversion of exchangeable shares into common stock, shares

24,571,166

Conversion of convertible debentures into common stock

$ 4

15,756

15,760

Conversion of convertible debentures into common stock, shares

3,750,000

Issuance of equity to noncontrolling interest holders

225

Preferred stock dividend

(2)

Other comprehensive loss

(1,916)

Net (loss) income

(46,693)

(1)

(46,694)

Sale of common stock under at-the- market offering, net of transaction costs

1,724

Balance at Mar. 31, 2026

$ 98

$ 924,802

$ (764,813)

$ (1,102)

$ 256

$ 159,241

Balance, shares at Mar. 31, 2026

97,721,696

[1]	- less than $1

OPTIONS, RESTRICTED STOCK UNITS AND WARRANTS (Details Narrative) - USD ($)

3 Months Ended

Mar. 31, 2026

Mar. 16, 2026

Feb. 06, 2026

Feb. 01, 2026

Dec. 30, 2025

Sep. 05, 2025

Mar. 31, 2026

Mar. 31, 2025

Dec. 29, 2025

Sep. 04, 2025

Jan. 12, 2024

Accumulated Other Comprehensive Income (Loss) [Line Items]

Sale of common stock under-at-the market offering, net of transaction costs, shares

3,750,000

Exercise price

$ 1.13

Granted shares

250,000

Weighted average exercise price

$ 3.21

Weighted average remaining contractual term

10 years

Share based compensation

$ 25,370,000

$ 2,074,000

Share based compensation expense

Unrecognized compensation expense

$ 0

Share price

$ 3.00

Weighted average period

1 year 3 months 29 days

Other than options grants, GDFV

5,903,316

Share based compensation, granted

2,965,000,000

Grant-date fair value

$ 1,830,000

Stock issued grant fair value

$ 1,724,000

3,882,000

Stock option description

i) 50,000 units upon launch of the REE Fund (subject to a dollar cap of $150); (ii) 100,000 units when AUM exceeds $500 million (subject to a dollar cap of $350); and (iii) 850,000 units when AUM exceeds $1 billion (subject to a dollar cap of $3,000)

Stock issued during the period, other

$ 818,000

Share-based compensation, description

The dollar caps limit the maximum value deliverable to the consultant regardless of the stock price at vesting. As of March 31, 2026, management assessed the probability of achieving each AUM-based performance condition on a tranche-by-tranche basis and concluded that no condition is probable. The launch of a REE Fund would require, among other things, formation of a legal entity, preparation of offering documents, establishment of custody and pricing infrastructure for rare earth elements, and satisfaction of applicable regulatory requirements — none of which had been initiated as of the reporting date. The AUM-based milestones ($500 million and $1 billion) are sequentially dependent on fund launch and were assessed as remote. Accordingly, no stock-based compensation expense was recognized during the three months ended March 31, 2026. The Company recognizes compensation cost only when achievement of the applicable performance condition is considered probable, on a straight-line basis over the requisite service period.

Weighted average Years

1 year 10 months 24 days

Maximum [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 12,000.00

Weighted average period

7 years 4 months 28 days

Grant-date fair value

$ 3,500,000

Share-Based Payment Arrangement, Tranche One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Other than options grants, GDFV

^[1]

3.56

Other than options grants, milestone

$ 5.00

Share-Based Payment Arrangement, Tranche Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 350

Other than options grants, GDFV

^[1]

3.55

Share-Based Payment Arrangement, Tranche Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

3,000

Other than options grants, GDFV

^[1]

3.57

Share Based Compensation Award Tranche Four [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Other than options grants, GDFV

^[1]

3.56

Share Based Compensation Award Tranche Five [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Other than options grants, GDFV

^[1]

3.54

Share Based Compensation Award Tranche [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 150

Third Party Consultant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Sale of common stock under-at-the market offering, net of transaction costs, shares

1,000,000

Share based compensation, granted

500,000

Viral Clear Pharmaceuticals Inc [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Shares available for future issuance

2,915,071

Common Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Sale of common stock under-at-the market offering, net of transaction costs, shares

4,403,166

Shares of its common stock, warrants

54,647

Stock issued grant fair value

$ 4,000

Stock issued during the period, conversion

$ 1,830,000

Stock issued during the period, other

3,500,000

1,000

Warrant [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Warrants to purchase common stock

87,984

Share price

$ 1.13

Common Stock One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 5.00

Share based compensation, granted

100,000

Common Stock Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 6.00

Share based compensation, granted

100,000

Common Stock Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 8.00

Share based compensation, granted

100,000

Common Stock Four [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 10.00

Share based compensation, granted

100,000

Common Stock Five [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share price

$ 12.00

Share based compensation, granted

100,000

Share-Based Payment Arrangement, Option [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share based compensation

$ 770,000

Share based compensation expense

40,000

Share-Based Payment Arrangement, Option [Member] | 2023 Long-Term Incentive Plan [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Sale of common stock under-at-the market offering, net of transaction costs, shares

18,109,340

22,494,324

10,359,211

Shares authorized

37,230,130

14,735,806

4,376,595

Restricted Stock Units (RSUs) [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share based compensation expense

24,545

$ 2,236

Unrecognized stock-based compensation cost

$ 24,545

Other than options grants, GDFV

8,868,316

Stock issued grant fair value

^[2]

$ 8,445,000

Restricted Stock Units (RSUs) [Member] | Viral Clear Pharmaceuticals Inc [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Other than options grants, GDFV

8,868,316,000

Weighted average grant date fair value

$ 3.01

Performance Shares [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Sale of common stock under-at-the market offering, net of transaction costs, shares

500,000

Share based compensation expense

$ 54,000

Weighted average grant date fair value

$ 500,000

Grant-date fair value

^[3]

$ 1,778,000

Stock issued grant fair value

$ 1,778,000

Stock issued during the period, conversion

$ 1,830,000

Stock issued during the period, conversion shares

1,000,000,000

Weighted average Years

5 years 6 months

Employee share based compensation

$ 0

Performance Shares [Member] | Share-Based Payment Arrangement, Tranche One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share based compensation expense

$ 17,000

Weighted average grant date fair value

$ 100,000

Grant-date fair value

^[3]

$ 356,000

Weighted average remaining contractual term

^[4]

3 years 5 months 4 days

Performance Shares [Member] | Share-Based Payment Arrangement, Tranche Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share based compensation expense

$ 12,000

Other than options grants, milestone

$ 6.00

Weighted average grant date fair value

$ 100,000

Grant-date fair value

^[3]

$ 355,000

Weighted average remaining contractual term

^[4]

4 years 6 months 29 days

Performance Shares [Member] | Share-Based Payment Arrangement, Tranche Three [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share based compensation expense

$ 9,000

Other than options grants, milestone

$ 8.00

Weighted average grant date fair value

$ 100,000

Grant-date fair value

^[3]

$ 357,000

Weighted average remaining contractual term

^[4]

5 years 11 months 26 days

Performance Shares [Member] | Share Based Compensation Award Tranche Four [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share based compensation expense

$ 8,000

Other than options grants, milestone

$ 10.00

Weighted average grant date fair value

$ 100,000

Grant-date fair value

^[3]

$ 356,000

Weighted average remaining contractual term

^[4]

6 years 10 months 2 days

Performance Shares [Member] | Share Based Compensation Award Tranche Five [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Share based compensation expense

$ 8,000

Other than options grants, milestone

$ 12.00

Weighted average grant date fair value

$ 100,000

Grant-date fair value

^[3]

$ 354,000

Weighted average remaining contractual term

^[4]

7 years 4 months 28 days

Restricted Stock [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Sale of common stock under-at-the market offering, net of transaction costs, shares

500,000

Restricted Stock One [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock issued grant fair shares vesting

300,000

Restricted Stock Two [Member]

Accumulated Other Comprehensive Income (Loss) [Line Items]

Stock issued grant fair shares vesting

200,000

[1]	GDFV per unit, determined using a Monte Carlo simulation model. The weighted-average grant-date fair value per unit for the stock price-based PSUs was $3.56.
[2]	Grant-date fair value (“GDFV”)
[3]	Aggregate fair value (“Agg FV”)
[4]	Derived service period (“DSP”)

RELATED PARTY TRANSACTIONS (Details Narrative) - USD ($) $ in Thousands	3 Months Ended
	Mar. 31, 2026	Dec. 31, 2025
Streamex Ltd [Member] \| General Counsel Officers [Member]
Related Party Transaction [Line Items]
Variable interst entity	$ 25
Related Party [Member]
Related Party Transaction [Line Items]
Other liabilities	$ 907	$ 66
Variable interest percentage	1.50%

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

+ Details

CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS (Tables)

3 Months Ended

Mar. 31, 2026

Debt Disclosure [Abstract]

SCHEDULE OF SETTLEMENT

In connection with the settlement, the Company recognized the following:

SCHEDULE OF SETTLEMENT


Loss on extinguishment of convertible debentures — prepayment premium	$	(3,500	)
Gain on derecognition of embedded derivative at settlement		443
Realized loss on extinguishment of convertible debentures	$	(3,057	)

SCHEDULE OF ESTIMATED GRANT DATE FAIR VALUE (Details) - $ / shares	3 Months Ended
	Mar. 31, 2026	Mar. 16, 2026	Jan. 12, 2024
Stock price	$ 3.58
Stock price		$ 3.00	$ 3.00
Expected volatility	152.90%
Interest rate	3.72%
Dividend yield	0.00%
Derived service period	1 year 3 months 29 days
Minimum [Member]
Stock price	$ 5,000.00
Derived service period	3 years 5 months 4 days
Maximum [Member]
Stock price	$ 12,000.00
Derived service period	7 years 4 months 28 days

CONVERTIBLE DEBENTURES AND RELATED DERIVATIVE INSTRUMENTS (Details Narrative) - USD ($) $ / shares in Units, $ in Thousands				3 Months Ended		12 Months Ended
	Dec. 17, 2027	Nov. 04, 2027	Feb. 06, 2026	Mar. 31, 2026	Mar. 31, 2025	Dec. 31, 2025	Dec. 17, 2025	Nov. 04, 2025
Debt Instrument [Line Items]
Face amount			$ 35,000				$ 50,000	$ 50,000
Interest rate effective percentage				4.00%			228.90%	393.70%
Conversion price			$ 4.00	$ 6.016
Share price				$ 4.00
Convertible debt				$ 50,000		$ 203
Debt instrument fair value				0
Interest expense				12,182
Amortization of discounts and issuance costs				11,979
Debt instrumental principal amount				0		50,000
Debt principal amount			$ 50,000
Converitible debt			38,021			38,021
Unamorization debt discount				11,979		11,979
Cash payoff			38,903	6,859		$ 20,316
Debt instrument periodic payment			3,500
Debt instrument accrued interest			$ 403
Principal conversion amount				$ 15,000
Number of shares issued			3,750,000
Common Stock [Member]
Debt Instrument [Line Items]
Conversion of convertible shares				24,571,166
Number of shares issued					4,403,166
Maximum [Member] \| Common Stock [Member]
Debt Instrument [Line Items]
Conversion of convertible shares				12,500,000
Minimum [Member]
Debt Instrument [Line Items]
Stated interest rate				17.60%
Subsequent Event [Member]
Debt Instrument [Line Items]
Stated interest rate	96.00%	96.00%
Interest rate effective percentage	4.00%	4.00%
Interest rate for basic	18.00%	18.00%
Share-Based Payment Arrangement, Tranche One [Member]
Debt Instrument [Line Items]
Face amount								$ 25,000
Share-Based Payment Arrangement, Tranche Two [Member]
Debt Instrument [Line Items]
Face amount							$ 25,000

SCHEDULE OF WARRANT ACTIVITY (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended	12 Months Ended
	Mar. 31, 2026	Dec. 31, 2025
Restructuring Cost and Reserve [Line Items]
Weighted-Average Remaining Contractual Term, Outstanding	1 year 10 months 24 days
Outstanding Aggregate Intrinsic Value	$ 6,744,540
Outstanding shares	1,647,885
Outstanding Aggregate Intrinsic Value	$ 1,709,540	$ 6,744,540
Warrants Vested and expected to vest, Aggregate Intrinsic Value	111,231
Warrants Exercisable, Aggregate Intrinsic Value	$ 111,231
BioSig AI Sciences, Inc. [Member]
Restructuring Cost and Reserve [Line Items]
Outstanding shares	1,735,869
Weighted-Average Exercise Price ending	$ 6.94
Weighted-Average Remaining Contractual Term, Outstanding	2 years 7 months 6 days	2 years 9 months 18 days
Outstanding Aggregate Intrinsic Value		$ 1,414,626
Issued
Exercised
Exercised	(87,984)
Weighted-Average Exercise Price Exercised	$ 0.95
Outstanding shares	1,647,885	1,735,869
Weighted-Average Exercise Price ending	$ 7.26	$ 6.94
Outstanding Aggregate Intrinsic Value	$ 111,231
Warrants Vested and expected to vest, Shares	1,647,885
Weighted-Average Exercise Price Vested and expected to vest	$ 7.26
Weighted-Average Remaining Contractual Term, Exercised	2 years 7 months 6 days
Warrants Exercisable, Shares	1,647,885
Weighted-Average Exercise Price Exercisable	$ 7.26
Weighted-Average Remaining Contractual Term Exercisable	2 years 7 months 6 days

NON-CONTROLLING INTEREST

3 Months Ended

Mar. 31, 2026

Noncontrolling Interest [Abstract]

NON-CONTROLLING INTEREST

NOTE 15 – NON-CONTROLLING INTEREST

As of March 31, 2026 and December 31, 2025, the Company had a majority interest in ViralClear of approximately 70% for both periods. As of March 31, 2026, and December 31, 2025, the Company had a majority interest in BioSig AI of approximately 84% for both periods. As of March 31, 2026, the Company consolidated Streamex Ltd. as a variable interest entity, with noncontrolling interest holders (consisting of two related party officers) holding approximately 1.5% of the outstanding GLDY Tokens. See Note 9, Streamex Ltd. (VIE), for additional information.

A reconciliation of ViralClear Pharmaceuticals, Inc., BioSig AI Sciences, Inc. and Streamex Ltd. non-controlling loss attributable to the Company:

Net loss attributable to the non-controlling interest for the three months ended March 31, 2026:

SCHEDULE OF NON-CONTROLLING INTEREST

	ViralClear Pharmaceuticals, Inc.			BioSig AI Sciences, Inc.			Streamex Ltd			Total
Net Income (loss)	$	-*		$	-		$	(155	)	$	(155	)
Noncontrolling interest’s weighted-average ownership percentage		30.0	%		16.0	%		0.2	%		0.01	%
Net income (loss) attributable to non-controlling interest	$	-*		$	-		$	(1	)	$	(1	)

Net loss attributable to the non-controlling interest for the three months ended March 31, 2025:

	ViralClear Pharmaceuticals, Inc.			BioSig AI Sciences, Inc.			Streamex Ltd			Total
Net loss	$	-*		$	75		$	-		$	75
Noncontrolling interest’s weighted-average ownership percentage		32	%		16	%		-	%		16	%
Net loss attributable to non-controlling interest	$	-*		$	12		$	-		$	12

Less than $0.5 thousand

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2026:

	ViralClear Pharmaceuticals, Inc.			BioSig AI Sciences, Inc.		Streamex Ltd			Total
Balance, January 1, 2026	$	(171	)	$	203	$	-		$	32
Issuance of equity to noncontrolling interest holders		-			-		225			225
Net income (loss) attributable to non-controlling interest		-			-		(1	)		(1	)
Balance, March 31, 2026	$	(171	)	$	203	$	224		$	256

The following table summarizes the changes in non-controlling interest for the three months ended March 31, 2025:

	ViralClear Pharmaceuticals, Inc.			BioSig AI Sciences, Inc.		Streamex Ltd		Total
Balance, January 1, 2025	$	(171	)	$	188	$	-	$	17
Net income (loss) attributable to non-controlling interest		-			12		-		12
Balance, March 31, 2025	$	(171	)	$	200	$	-	$	29